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Pharmacologic Reversal Of Drp1-Dependent Mitochondrial Fragmentation, A
Homeostatic Mechanism In Friedreich Ataxia
Abstract
Friedreich ataxia is an autosomal recessive neurodegenerative disease that presents during adolescence
that causes dysmetria, dysarthria, and ataxia; as the disease progresses, patients develop
cardiomyopathy, which is the typical cause of death. This disease, currently without an FDA-approved
therapy, is characterized by deficiency in frataxin, a small mitochondrial protein that is highly conserved
across species. GAA trinucleotide repeat expansions in the first intron of the FXN gene decrease
transcription of this gene, resulting in lower frataxin protein levels. Frataxin participates in iron-sulfur
cluster biosynthesis, iron chaperoning, and in maintaining iron homeostasis; thus, frataxin deficiency
impairs the functions of proteins that are dependent upon iron-sulfur cluster prosthetic groups. Aconitase
and Complex II of the electron transport chain, for example, rely upon iron-sulfur clusters for their roles in
ATP synthesis. Therefore, Friedreich ataxia patients also exhibit decreased ATP levels in addition to other
mitochondrial impairments. Investigating the effects of the disease and potential therapeutics on
mitochondrial functioning is therefore of critical importance to develop a viable therapeutic strategy for
this disease. Alterations to mitochondrial morphology are associated with impairments to mitochondrial
functioning in numerous neurodegenerative diseases; investigating the morphological changes that occur
through mitochondrial fission is therefore critical to understanding the impact of this disease on the
mitochondria. Mitochondrial fission is executed by Drp1, a GTPase, so utilizing the specific Drp1 inhibitor
P110 provides an invaluable tool for studying morphological changes. Additionally, mitochondrial
morphology is greatly affected by cardiolipin, a four-tailed phospholipid that anchors the electron
transport chain. The electrostatic interactions that are critical to cardiolipin’s functions are disrupted by
oxidative stress, so the cardiolipin-stabilizing compound SS-31 may provide bioenergetic benefits to
Friedreich ataxia patients. This dissertation examines the effects of Friedreich ataxia on mitochondrial
morphology and function. It establishes that frataxin deficiency increases mitochondrial fragmentation
that is dependent upon Drp1 activity. Furthermore, it demonstrates that SS-31 may also reverse
fragmentation in this disease and that this compound operates on the same pathway as P110. Finally, it
provides direction for future studies regarding mitochondrial-based therapeutic strategies for FRDA.
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ABSTRACT
PHARMACOLOGIC REVERSAL OF DRP1-DEPENDENT MITOCHONDRIAL
FRAGMENTATION, A HOMEOSTATIC MECHANISM IN FRIEDREICH ATAXIA
Joseph Johnson
David Lynch

Friedreich ataxia is an autosomal recessive neurodegenerative disease that presents
during adolescence that causes dysmetria, dysarthria, and ataxia; as the disease progresses,
patients develop cardiomyopathy, which is the typical cause of death. This disease, currently
without an FDA-approved therapy, is characterized by deficiency in frataxin, a small mitochondrial
protein that is highly conserved across species. GAA trinucleotide repeat expansions in the first
intron of the FXN gene decrease transcription of this gene, resulting in lower frataxin protein
levels. Frataxin participates in iron-sulfur cluster biosynthesis, iron chaperoning, and in
maintaining iron homeostasis; thus, frataxin deficiency impairs the functions of proteins that are
dependent upon iron-sulfur cluster prosthetic groups. Aconitase and Complex II of the electron
transport chain, for example, rely upon iron-sulfur clusters for their roles in ATP synthesis.
Therefore, Friedreich ataxia patients also exhibit decreased ATP levels in addition to other
mitochondrial impairments. Investigating the effects of the disease and potential therapeutics on
mitochondrial functioning is therefore of critical importance to develop a viable therapeutic
strategy for this disease. Alterations to mitochondrial morphology are associated with
impairments to mitochondrial functioning in numerous neurodegenerative diseases; investigating
the morphological changes that occur through mitochondrial fission is therefore critical to
understanding the impact of this disease on the mitochondria. Mitochondrial fission is executed
by Drp1, a GTPase, so utilizing the specific Drp1 inhibitor P110 provides an invaluable tool for
studying morphological changes. Additionally, mitochondrial morphology is greatly affected by
cardiolipin, a four-tailed phospholipid that anchors the electron transport chain. The electrostatic
interactions that are critical to cardiolipin’s functions are disrupted by oxidative stress, so the
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cardiolipin-stabilizing compound SS-31 may provide bioenergetic benefits to Friedreich ataxia
patients. This dissertation examines the effects of Friedreich ataxia on mitochondrial morphology
and function. It establishes that frataxin deficiency increases mitochondrial fragmentation that is
dependent upon Drp1 activity. Furthermore, it demonstrates that SS-31 may also reverse
fragmentation in this disease and that this compound operates on the same pathway as P110.
Finally, it provides direction for future studies regarding mitochondrial-based therapeutic
strategies for FRDA.
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ABBREVIATIONS

(S616) phospho-Drp1- Drp1 phosphorylated at residue Serine 616
AD- Alzheimer disease
ALS- Amyotrophic lateral sclerosis
ARE- antioxidant response element
ATP- adenosine triphosphate
Drp1- Dynamin-related protein 1 (DNM1)
ECL- enhanced chemiluminescence
ER- endoplasmic reticulum
ETC- electron transport chain
FRDA- Friedreich ataxia
Fis1- mitochondrial fission protein 1
FXN- frataxin
GAA- guanine-adenine-adenine
GTP- guanosine triphosphate
HD- Huntington disease
IMM- inner mitochondrial membrane
ISC- iron-sulfur cluster
KIKO- Knock-in/Knockout
MAM- mitochondrial associated membrane
Mcl1- myeloid cell leukemia 1
Mff- mitochondrial fission factor
MiD49- mitochondrial division protein of 49 kD
MiD51- mitochondrial division protein of 51 kD
miRNA- micro-RNA
MS- multiple sclerosis
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mtDNA- mitochondrial DNA
Nrf2- nuclear factor erythroid 2-related factor 2
OMM- outer mitochondrial membrane
PBS- phosphate-buffered saline
PD- Parkinson disease
ROS- reactive oxygen species
SS-31- Szeto-Schiller compound 31
TBS-T- tris-buffered saline with 1% tween-20
KIWT- Knock-in/Wild type
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CHAPTER 1- INTRODUCTION
1.1 Friedreich ataxia

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disease
characterized by chronic deficiency of frataxin (FXN)1-3. FRDA affects approximately 1:50000
individuals, although the prevalence varies greatly between genetic populations; African and
Asian populations have far fewer incidences of this disease than European populations 4,5. FRDA
causes dysmetria, dysarthria, ataxia, fatigue, and an unstable gait, and further complications
often include vision loss and diabetes6-10. Most patients develop left ventricular hypertrophy11.
Atrophy in the cerebellum, particularly the dentate nucleus, as well as upper motor neuron
degeneration primarily contribute to these disease features, and patients also may exhibit large
sensory neuron degradation in the dorsal root ganglia and spinal cord8,12,13. The typical life
expectancy of FRDA patients is approximately 40 years, and despite growing research in
potential therapies, there is currently no cure for the disease14-16.
Seven exons comprise the frataxin gene (the last two of which represent alternative
isoforms of the gene); however, intron 1 plays the most critical role in the development of
FRDA17. Guanine-adenine-adenine (GAA) trinucleotide repeats exist in the first intron of FXN for
all individuals; while unaffected individuals have fewer than 40 GAA repeats, FRDA patients may
have 70-1700 GAA repeats, and longer repeat lengths correlate with lower levels of FXN
mRNA18. The majority of FRDA patients have GAA repeat expansion on both alleles. For these
typical cases of FRDA, the length of the shorter GAA repeat inversely correlates with the age of
disease onset as well as disease severity19,20. Typical FRDA patients still produce functional FXN
but exhibit approximately less than 30% the levels of FXN observed in unaffected individuals, with
some variation in levels between different tissue types21. While the vast majority of FRDA cases
result from GAA repeat expansions on both chromosome, 2-5% of FRDA patients are compound
heterozygotes in which the trinucleotide repeat expansion occurs on one allele while other
mutation(s) exist on the other allele22-24. The percentage of FRDA cases caused by compound
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heterozygotic mutations is approximately the same across populations, despite the overall
frequency of FRDA varying between different populations 24,25.
Several hypotheses exist as to why GAA repeat expansions decrease transcription of
FXN26. The trinucleotide repeats may result in the formation of DNA-RNA hybrid structures
during transcription, causing RNA polymerase to detach from the DNA prematurely and may
further expand the number of GAA repeats27,28. Alternatively, the trinucleotide repeats may
increase DNA methylation on CpG islands in the promoter of FXN, resulting in gene silencing29-31.
The relationship between GAA trinucleotide repeats, FXN levels, and disease severity remains an
important avenue of investigation for the field as the insights gained from such studies may
elucidate potential therapeutic targets.

1.2 FXN function

As FRDA is characterized by FXN deficiency, the role of this evolutionarily conserved
protein has been widely studied and debated32-34. FXN is a 210 amino acid nuclear encoded
protein with an N-terminal mitochondrial targeting domain; following translation, the precursor
FXN is imported to the mitochondria where is undergoes two cleavage events by mitochondrial
processing peptidase, resulting in the mature form of FXN (amino acids 81-210)35,36. The
sequence and crystal structure are highly conserved across species including yeast (S.
cerevisiae) and bacteria (E. coli)37,38. This strict conservation suggests that FXN has a vital
function in cellular operations.
The role of FXN is inextricably linked to the cellular functions of iron. This essential metal
plays critical roles in numerous cellular functions including oxygen transport, neurotransmitter
regulation, and DNA synthesis39,40. Additionally, iron plays several critical roles in cellular
metabolism; iron’s functions in metabolic pathways and its interactions with FXN in these
pathways are at the crux of FRDA pathophysiology.
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FXN primarily localizes to the mitochondrial matrix where it may bind two Fe(II) atoms41.
Binding Fe(II) atoms suggests that FXN may play a role iron storage and thus protect the cell
from iron overload; however, this function is redundant of mitochondrial ferritin42. The primary
role of FXN, therefore, lies in biosynthesis of iron-sulfur clusters (ISC), prosthetic groups critical
for numerous mitochondrial enzymes. Frataxin knockout results in intramitochondrial iron
accumulation as well as deficiency in ISC-containing enzymes, like aconitase and Complexes I
and II of the ETC43-45. Thus, FXN deficiency in FRDA leads to intramitochondrial iron
accumulation and decreases ISC biosynthesis, resulting in impaired mitochondrial functioning.

1.3 Electron transport chain in functional mitochondria

The electron transport chain (ETC) generates an electron gradient across the inner
mitochondrial membrane (IMM) that is used for ATP synthesis. The ETC is comprised of four
major multi-protein complexes: NADH-ubiquinone oxidoreductase, succinate dehydrogenase,
ubiquinol-cytochrome c oxidoreductase, and cytochrome c oxidase (Complexes I-IV
respectively)46. These four complexes are anchored to the IMM while two mobile components,
coenzyme Q and cytochrome c, facilitate electron transfer across the four complexes 46. ATP
synthase (Complex V) utilizes the electron gradient generated by the ETC to synthesize ATP
through oxidative phosphorylation, and this mechanism is the cell’s primary method of generating
ATP46.
Complexes I and II of the ETC, as well as aconitase in the TCA and numerous other
enzymes, rely upon iron-sulfur clusters (ISCs) to function47. These prosthetic groups may take on
various structures, often bind to cysteine residues, and are highly conserved across species 47.
These bioinorganic molecules efficiently transfer electrons across proteins; this property allows
ISCs to serve a variety of functions in metabolism, DNA repair, and other critical cellular
pathways47. ISC biosynthesis impairment in FRDA is detrimental because of the ISC ubiquity in
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critical cellular processes. This dissertation will investigate the mitochondrial dysfunction
resulting from FXN deficiency and the subsequent ISC biosynthesis impairment in FRDA.

1.4 Mitochondrial dysfunction and fragmentation in neurodegenerative disease

Mitochondria are highly dynamic organelles that alter their morphology in response to
various environmental and cellular stressors48-53. While a correlation exists between
mitochondrial morphology and metabolic functioning, the precise metabolic effects of altered
morphology are dependent upon the tissue type and disease state. Generally, however, the
mitochondria of healthy cells fuse into elongated, tubular structures54,55. When a cell experiences
stress, particularly oxidative stress or accumulation of reactive oxygen species (ROS), the
mitochondria fragment, forming punctate structures. In certain tissue types and disease states,
this fragmentation may represent a homeostatic response intended to target dysfunctional
mitochondria for mitophagy or to increase the overall mitochondrial surface area56-58.
In numerous disease states, however, excessive mitochondrial fragmentation appears to
be a detrimental consequence of disease. Particularly in neurodegenerative disease like
Parkinson disease (PD) and Amyotrophic lateral sclerosis (ALS), mitochondrial fragmentation
results in impaired metabolic functioning59,60. In these and many other diseases in which
mitochondrial fragmentation has been studied, however, mitochondrial fragmentation represents
a secondary disease feature, downstream of the primary cause of disease. Contrast this with
FRDA, a disease with mitochondrial dysfunction as the immediate consequence of frataxin
deficiency. Therefore, while mitochondrial fragmentation may be detrimental in diseases where
mitochondrial dysfunction is a secondary feature, mitochondrial fragmentation may represent a
homeostatic response in FRDA and other diseases with mitochondrial dysfunction as a primary
consequence of the disease.
The GTPase Dynamin-related protein 1 (Drp1) executes mitochondrial fragmentation
(Fig. 1.4.1). When phosphorylated at its Serine 616 residue (S585 in rats) by cyclin-dependent
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kinase 1 (CDK1) or CDK561,62, (Ser616) phospho-Drp1 is chaperoned to the mitochondria by the
protein myeloid cell leukemia 1 (Mcl1)63. (Ser616) phospho-Drp1 homo-oligomerizes and binds
to adaptor proteins including mff, fis1, MiD49, and MiD5164. This typically occurs at mitochondrial
associated membranes (MAMs) which are contact points between the mitochondria and the
endoplasmic reticulum (ER)65,66. In addition to adapter proteins, the four-tailed phospholipid
cardiolipin (CL) facilitates (Ser616) phospho-Drp1 binding to and fragmenting the
mitochondria67,68. The oligomerized (Ser616) phospho-Drp1 forms a ring surrounding the
mitochondria and mechanically severs this organelle through GTPase activity 69. The (Ser616)
phospho-Drp1 then dissociates from the mitochondria and may undergo other post-translational
modifications to serve other functions in the cell or may be targeted for degradation69.
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Fig. 1.4.1 Visual representation of mitochondrial fragmentation. Unmodified Drp1 is dispersed in
the cytosol (A). CDK1 phosphorylates Drp1 at Ser616, causing in (Ser616) phospho-Drp1 to be
chaperoned to the mitochondria where this protein homo-oligomerizes (B). Through GTPase
activity, (Ser616) phospho-Drp1 mechanically severs the mitochondria (C). Individual
mitochondrial fragments result, and (Ser616) phospho-Drp1 dissociates from the mitochondria
(D). A representative immunofluorescence ICC image of (Ser616) phospho-Drp1 localized to
sites of mitochondrial fragmentation is shown in (E).
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Reversing mitochondrial fragmentation is currently a highly studied approach for treating
neurodegenerative diseases; a primary goal of this thesis is to determine whether such an
approach is viable for treating FRDA or if fragmentation is a beneficial, homeostatic response in
this disease.

1.5 P110 and SS-31 as potential therapies for neurodegenerative disease

Peptide 110 (P110) is a small peptide that inhibits the GTPase activity of Drp1 and
prevents (Ser616) phospho-Drp1 from binding to the mitochondria70. To improve transport of this
peptide into the cell, a cell-penetrating TAT domain may be added to the N-terminus of P110. At
concentrations at or below 1 µM, P110 reverses mitochondrial fragmentation, improves
mitochondrial functioning, inhibits ROS production, and is neuroprotective in models of Parkinson
Disease (PD), Huntington Disease (HD), and Multiple Sclerosis (MS)71-73. Additionally, Drp1
inhibition ameliorates several pathologic hallmarks of Alzheimer Disease (AD) 74. P110 treatment,
moreover, reverses mitochondrial fragmentation and improves cellular bioenergetics in several
cardiomyopathy disease models75,76. Despite extensive investigation in other neurodegenerative
diseases, the effects of P110 on mitochondrial morphology and metabolic function have not
previously been studied in sub-acute or chronic models of FRDA.
Szeto-Schiller compound 31 (SS-31) is a small peptide that stabilizes cardiolipin,
although the mechanisms by which SS-31 performs this function as well as the nature of this
stabilization are not yet fully defined77. Cardiolipin is a four-tailed phospholipid that predominantly
localizes to the inner mitochondrial membrane (IMM) and plays critical roles in both mitochondrial
bioenergetics and apoptosis78-80. The steric structure of cardiolipin forms cristae in the IMM,
brings the complexes of the ETC in close proximity, and anchors cytochrome c. Exposure to
certain stressors, particularly oxidative stress, disrupts the electrostatic interactions binding
cardiolipin to these proteins, resulting in impaired ETC functioning and cytochrome c release
leading to apoptosis81. SS-31 may prevent disruption of these electrostatic interactions or
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otherwise prevent lipid peroxidation to increase ATP synthesis and prevent cytochrome c
release82.
SS-31 is neuroprotective and improves cellular respiration in several disease models83,84.
Additionally, SS-31 reverses excessive mitochondrial fragmentation is models of mitochondrial
cardiomyopathies85,86. SS-31 increases the level of frataxin and decreases ROS accumulation in
one FRDA patient-derived lymphoblast cell line87.
A primary goal of this dissertation is to compare the effects of TAT-P110 and SS-31 on
mitochondrial morphology and function across sub-acute and chronic cellular models of FRDA.
This thesis will investigate whether the effects of SS-31 are dependent upon Drp1 activity and
whether SS-31 and TAT-P110 affect the same cellular pathway. Additionally, this thesis will
explore the effects of mitochondrial fragmentation in FRDA, whether mitochondrial fragmentation
may be reversed by these peptides, and whether mitochondrial fragmentation represents a viable
therapeutic target for the treatment of FRDA.

1.6 Nrf2 involvement in disease state
FRDA patient cells have an impaired ability to cope with oxidative stress, typically leading
to ROS accumulation and may increase susceptibility to DNA damage and cell death. Typically,
when a cell experiences oxidative stress, nuclear factor erythroid 2-related factor 2 (Nrf2) is
upregulated88. This master transcriptional regulator promotes expression of antioxidant response
element (ARE) genes. ARE expression allows the cell to successfully reduce the accumulated
ROS, so Nrf2 is highly upregulated in many disease states in which the cell would otherwise
experience oxidative stress. However, in FRDA, Nrf2 is paradoxically decreased 89,90.
Although the heart is susceptible to oxidative damage, antioxidant enzyme activity is
lower in cardiac tissue than in other tissues91. Because oxidative stress contributes to many
common forms of cardiac dysfunction, Nrf2 activators may be useful in counteracting the
oxidative damage resulting from cardiac diseases92. This function may prove particularly
beneficial in FRDA since cardiac dysfunction is the typical cause of death for this disease.
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Moreover, ferroptosis, an iron-dependent form of cell death that occurs independently of
apoptosis, relies upon oxidation of polyunsaturated fatty acids (PUFAs) and may play a role in
neurodegenerative diseases93. Nrf2 activation may therefore counteract ferroptosis by limiting
lipid peroxidation93. Ferroptosis is a pathogenic mechanism in FRDA, and ferroptosis inhibitors
appear to be beneficial in suppressing this pathway in FRDA cellular models 94. Nrf2 activating
drugs may therefore also prove beneficial by inhibiting ferroptosis in FRDA patients.
In addition to its antioxidant activity, Nrf2 also plays a critical role in suppressing chronic
inflammation, a pathogenic feature in a number of neurodegenerative diseases. Toll-like
receptors (TLRs) signal for increased production of cytokines, chemokines, and interferons in
response to various environmental stressors and endogenous pro-inflammatory stimuli95. While
this inflammation response may represent a homeostatic mechanism acutely, chronic activation
of this pathway becomes detrimental for the cell95. Moreover, chronic inflammation is associated
with numerous neurodegenerative diseases, including Multiple Sclerosis, Alzheimer Disease, and
Parkinson Disease96,97. This chronic inflammation appears to result from disruptions to regulatory
mechanism, and therefore, pharmacologic regulation of inflammation may prove beneficial for
ameliorating the effects of chronic inflammation in neurodegenerative diseases. Nrf2 activation
suppresses inflammation by inhibiting transcription of pro-inflammatory cytokine genes98.
Although the antioxidant activity of Nrf2-target genes may also improve the cell’s ability to
respond to chronic inflammation be reducing free radicals, this transcriptional regulation of proinflammatory signals is independent of Nrf2 redox control98.

1.7 Approaches to upregulating Nrf2
Nrf2-activating drugs are therefore undergoing investigation for potential use in treating
FRDA. One mechanism of action for Nrf2-activating drugs is inhibiting the interaction between
Nrf2 and Keap1, an E3 ubiquitin ligase that targets Nrf2 for degradation99. This is the mechanism
of action for drugs like omaveloxolone100. However, Nrf2 protein levels may be regulated
independently of Keap1; Hrd1 (synoviolin), another E3 ubiquitin ligase, ubiquitinates Nrf2, as well
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as other mitochondrial biogenesis proteins, independently of Keap1 activity 101,102. LS-102, an
Hrd1 inhibitor, may consequently upregulate Nrf2102-104.
As KEAP1 appears to be the most critical regulator of Nrf2 levels, alterations to KEAP1
expression and/or activity consequently impact Nrf2. KEAP1 hypermethylation silences this gene
resulting in Nrf2 accumulation105. Moreover, several small molecules that inhibit the interaction
between KEAP1 and Nrf2 have also been developed106. Preventing this interaction thus prevents
Nrf2 degradation, causing further accumulation of this protein.
Several cysteine residues on KEAP1 perform a redox-sensing function on this protein106.
Because these residues are susceptible to electrophilic attack and modification, they make
appropriate targets for pharmacologic KEAP1 inhibitors. In addition to RTA-408, bardoxelone
methyl, and dimethyl fumarate, several other drug candidates that electrophilically modify KEAP1
cysteine residues are currently at various phases in clinical trials for neurodegenerative and
neurologic diseases, various cancers, and diabetes106.
In addition to ubiquitylation by KEAP1, micro-RNAs (miRNAs) also post-transcriptionally
regulate Nrf2 levels107. Numerous short, single-stranded miRNAs negatively regulate Nrf2
expression in reticulocytes and cancer cells108-110. Utilizing such miRNAs may prove to be an
useful therapeutic strategy as an alternative or supplement to KEAP1 inhibition.
Nrf2 activity may also be regulated through alterations to its subcellular localization.
Progerin protein sequesters Nrf2 outside the nucleus, and this cytosolic localization impairs Nrf2
activity111. Progerin is constitutively expressed in patients with Hutchinson-Gilford progeria
syndrome, so Nrf2 activity impairment resulting in increased oxidative damage may represent a
mechanism for disease pathogenesis111,112.

1.8 Materials and Methods
Cell culture
Skin fibroblasts were derived from 5 FRDA patients and 1 healthy control. These
fibroblasts were cultured in DMEM/F12 medium containing 1% Penicillin/Streptomycin, 1% non-
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essential amino acids, and 10% fetal bovine serum; the antibiotics were omitted for experiments
involving transfection as the combination of reagents may be toxic to the cells. Cell cultures were
maintained in 10cm plates; experiments were performed in 12-well plates. 24 hours prior to an
experiment, cells were seeded at a density of 5x104 cells/well in a 12-well plate. The cells were
incubated at 37°C with 5% CO2.
siRNA knockdown
The cell culture conditions listed above were followed. The sequence for FXN-targeting
siRNA is GAACCUAUGUGAUCAACAAGCAGAC (Integrated DNA Technology), and the nontargeting control is Stealth RNAi siRNA Negative Control (Invitrogen, 12935100). siRNA
transfection was performed 24 hours after plating the cells. 2.5 µL of 20 µM siRNA and 5 µL
Lipofectamine RNAi Max were combined with 275 µL of Opti-MEM, and the mixture was
incubated at room temperature for 10 minutes. 85 µL of this mixture were then added to each
well, and the transfected cells were incubated at 37˚C with 5% CO 2 for 72 hours. At this time,
lysates were collected for Western blots, cells were mounted to coverslips for
immunocytochemistry (ICC), or the ATP assay was performed (see relevant subsections in
Materials and Methods for further details).
SS-31 in cell culture
SS-31 was provided by Stealth BioTherapeutics. The drug was reconstituted in sterile
water to a concentration of 1mM; this stock solution and aliquots of various working
concentrations were stored at -20° C until use. 24 hours after plating, cell cultures were treated
with 1 µM SS-31 or water as the vehicle control for 72 hours.
TAT-P110
TAT-P110 and an inactive, scrambled form of this peptide were obtained from Genscript.
The sequence of TAT-P110 is as follows: YGRKKRRQRRRGGDLLPRGT with C-terminal
amidation. The sequence of scrambled TAT-P110 is as follows: YGRKKRRQRRRGGTLGRLPD
with C-terminal amidation. Both of these peptides contain the cell-penetrating TAT sequence on
the N-terminal (amino acid residues 1-13 in the sequences listed above). Drug treatment began
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24 hours after plating. Cell cultures were treated with 1 µM TAT-P110 or 1 µM scrambled peptide
for 72 hours. For experiments involving the combination of SS-31 and TAT-P110, cells were
simultaneously treated with 1 µM SS-31 and 1 µM TAT-P110 for 72 hours.
Cell lysate preparation
RIPA buffer (150mM Sodium chloride, 1mM EDTA, 100 mM Tris-HCl pH 7.4, 1% Triton-X
100, 0.5% Sodium deoxycholate, and on the day of use 1:500 EDTA-free protease inhibitor
cocktail III) was used for cell lysis. 150 µM RIPA buffer were added to each well of the plate.
The wells were vigorously scraped for 30 sec., and the resulting cell lysates were collected in
microcentrifuge tubes. The cell lysates were stored at -20° for less than one week before
Western blot analysis.
Antibodies
-actin (Abcam, Cell Signaling Technology, 3700S, 1:1000 for WB), -Drp1
(Abcam, ab184247, 1:250 for ICC, 1:1000 for WB), α-phospho Drp1(S616) (Cell Signaling
Technology, 3455S, 1:250 for ICC, 1:1000 for WB), α-FXN (Abcam, ab110328, 1:1000 for
WB), -GRP75 (Abcam, ab2799, 1:250 for ICC).
Western blot analysis
The protein concentration in cell lysates was quantified using the Pierce BCA Protein
Assay Kit (Thermo Fisher Scientific catalog #23225) following the included protocol. A volume of
cell lysate necessary for 20 µg of protein was mixed with 2µL NuPAGE 10x sample reducing
agent (Thermo Fisher catalog #NP0009), 5µL NuPAGE 4x LDS sample buffer (Thermo Fisher
catalog #NP0007), and sterile water to a total volume of 20 µL. Samples were then added to
each well of a 10-, 12-, or 15-well NuPAGE 4-12% Bis-Tris polyacrylamide gel, and 5 µL of BioRad Precision Plus Dual Colored Standards was added to one well. MES SDS Running Buffer
was added to the apparatus, and the gel was run at 120V for 1 hour 30 minutes. The proteins
were transferred to a 0.45 µm nitrocellulose membrane using a wet transfer apparatus running at
95V for 1 hour 15 minutes. Following transfer, the membrane was blocked for one hour at room
temperature using 3% milk diluted in TBS-T. The membrane was incubated with the listed

12

dilution of primary antibody overnight at 4°C, then washed 3 times (5-10 minutes each) with TBST, and finally incubated with the listed dilution of secondary antibody (appropriate to the species
from which the primary antibody was isolated) for 1 hour at room temperature. The membrane
was washed 3 times (5-10 minutes each) with TBS-T then incubated with 2µL Pierce ECL
Western blotting substrate (Thermo Fisher catalog #32106). The ECL substrate was removed,
and the blot was imaged using a camera apparatus designed to capture ECL. Protein levels
were quantified using ImageJ software (NIH). 3-5 replicates for each experiment were quantified
in this way.
ATP level assay
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570) was utilized to
assess the relative level of ATP in fibroblasts. 5x104 cells were seeded in each well of a 12-well
plate, following the above cell culture protocol. After the appropriate drug treatment, media was
removed and 500 µL 0.05% trypsin was added to each well until the cells detached from the
plate. The cells were centrifuged at 1000 rcf for 10 minutes and resuspended in 1mL cell culture
media. 5x103 cells were added to each well of a 96 well plate, and the included protocol included
with the assay kit was performed as written. Luminescence was measured using a Synergy 2
Multi-Mode microplate reader using the CellTiter-Glo protocol with a 0.5 sec. integration time.
The amount of luminescence was recorded, serving as a proxy for the relative ATP level.
Immunocytochemistry and immunofluorescence imaging
A 1cm round glass coverslip was added to each well of a 12-well plate. Fibroblasts were
then seeded in each well following the appropriate cell culture and treatment conditions as listed
above. After treatment, media was removed and cells were fixed with 4% paraformaldehyde in
PBS for 10 minutes at 4°C. 5% normal goat serum, 1 % bovine serum albumin, and 0.3%
(vol/vol) Triton X-100 in PBS at room temperature for 1 hour. The coverslips were then incubated
with primary antibodies to GRP75 (mitochondrial marker) and (Ser616) phospho-Drp1 at the
dilution listed above at 4°C overnight. After 3 washes (5-10 minutes each) in PBS, the coverslips
were incubated with secondary antibodies (to the species from which the primary antibodies were
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isolated) conjugated to Alexa Fluor 488 or 568 (Invitrogen) at room temperature for 1 hour 30
minutes. After 3 washes (5-10 minutes each) in PBS, the coverslips were mounted to slides
using Vectashield with DAPI (Vector Laboratories). Fluorescence images were obtained with

Leica DM6000 microscope. The slides were sequentially imaged for (Ser616) phosphoDrp1 and GRP75 staining.
Quantification of Mitochondrial Fragmentation
The field’s previously standard method for quantifying mitochondrial fragmentation
involved a blinded individual counting the number of cells in fluorescence images that appeared
to have tubular or punctate mitochondria. While statistically significant preliminary results were
obtained using this method, it lacks a high degree of objectivity, rigor, and reproducibility. To
combat this, the author of this dissertation developed a novel method of quantifying mitochondrial
fragmentation that improves upon rigor and reproducibility and that provides a more quantitative
result for such experiments.
A confocal immunofluorescence image of cells stained for a mitochondrial marker is
imported to ImageJ software (NIH) and is converted to a black and white image. A threshold is
set to eliminate background noise, and this setting is kept constant for all images analyzed within
an experiment. A single cell is demarcated using the polyhedron line tool, and the software
quantifies the number of mitochondrial fragments within the demarcated area (a mitochondrial
fragment is denoted as group of black pixels surrounded by white pixels). Fig. 1.8.1 offers a
visual representation of this quantification method.
A minimum of 30 cells from each of 3 (healthy) or 9 (FRDA) biological replicates were
quantified using the previously standard method. A minimum of 20 cells per group from each of
2-3 biological replicates (each with 3 technical replicates) were quantified using the novel method.
Validation of novel method
To validate this novel method of quantifying mitochondrial fragmentation, results were
analyzed using both the previous and the novel methods. The results of this novel method
parallel the results of the previously standard method (Fig. 1.8.2). Reference sections 2.3 and
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2.4 for the full experimental designs and data used in making this comparison. The results of
using these two methods are highly similar validating this novel method as a reliable tool by which
to quantify mitochondrial fragmentation. Because the novel method is more quantitative, more
rigorous, more reproducible, and less time consuming, this method was used throughout this
dissertation. The author recommends other groups use this method for experiments requiring the
quantification of mitochondrial fragmentation.
(Ser616) phospho-Drp1 cluster quantification
The number of (Ser616) phospho-Drp1 clusters per cell were quantified in much the
same way as the number of mitochondrial fragments (see above). The only exception is that
fluorescence images of (Ser616) phospho-Drp1 staining were imported to ImageJ. In this
method, a (Ser616) phospho-Drp1 cluster is denoted as a group of black pixels surrounded by
white pixels. The number of (Ser616) phospho-Drp1 clusters per cell were quantified for at least
20 cells from each of 3 biological replicates (each with 3 technical replicates).
Mouse Model
All experiments performed on mouse models adhered to an IACUC-approved protocol.
The Knock in/Knockout (KIKO) mouse model (Jackson Laboratories #012329 B6.CgFxn(tm1.1Pand) Fxn(tm1Mkn/J)) has one null FXN allele and a humanized expansion sequence
in the second FXN allele. This model exhibits mitochondrial deficits, decreased levels of
mitochondrial proteins, and neurobehavioral deficits consistent with FRDA patients113-115. The
results of this compound heterozygote model were compared to the Knock in/Wild type (KIWT)
control. This control model has one wild type FXN allele and a humanized expansion sequence
in the second FXN allele.
SS-31 in Mouse Model
24 mice (12 KIWT and 12 KIKO) were used for these experiments with even numbers of
male and female mice in each group. Half of the mice were subcutaneously injected with 5 mg
SS-31 per 1 kg bodyweight while the other half were injected with the same amount of saline
solution as a vehicle control. The mice were approximately 3 months of age at the start of the
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experiments. The mice were injected for 5 consecutive days, followed by 2 days without
injections, and 5 more consecutive injection days. Mice were sacrificed via isoflurane and
decapitation approximately 2 hours after the final injection. Tissues were harvested immediately.
The cerebella were homogenized using RIPA buffer and prepared for Western blot analysis
following the previously outlined protocol.
Transcript level analysis
RNA transcript levels from fibroblasts derived from 17 healthy control individuals and 18
FRDA patients were assessed by interrogating the publicly accessible dataset GSE104288,
available on the NCBI Gene Expression Omnibus116. The transcript levels were previously
normalized for analysis following RNA sequencing, and the levels of 16531 gene transcripts were
reported116. R programming language and tidyverse packages were used to write a script that
interrogates this database for the transcript levels of genes relevant to mitochondrial dysfunction
in FRDA (Appendix). To validate the functionality of this code in conjunction with the RNA-seq
database, the level of FXN transcripts was assessed; in accordance with well-established
literature, the script confirms decreased FXN transcript levels in FRDA patients (Appendix).
Statistical Analysis
All experiments were performed according to a preset plan, including the number of
replicates. Graphs display the mean of the data ± S.E.M. Mitochondrial fragmentation and
(Ser616) phospho-Drp1 clustering were analyzed using two-tailed, independent samples t-test.
Western blot quantifications and ATP assay results were analyzed in R using Wilcoxon rank-sum
test. Statistical significance was set at p<0.05, and a non-significant trend was set at p<0.2.
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Fig. 1.8.1 Novel method for quantifying mitochondrial network fragmentation. An
immunofluorescence ICC cell culture image is imported to ImageJ (A). The color channels are
split such that only the channel for mitochondrial staining is displayed, in this case the green
channel (B). A threshold is set to eliminate background (C). A single cell is demarcated using
the polygon tool (D). The number of particles (defined as a group of black pixels surrounded by
white pixels) is quantified (E). This is the number of mitochondrial fragments per cell and may be
used for further statistical analyses.
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Fig. 1.8.2 Validation of novel method for quantifying mitochondrial network fragmentation. The
field’s previously standard method for quantifying mitochondrial fragmentation involved a blinded
individual counting the number of cells that appear to have fragmented or tubular mitochondria,
and the resulting data shows a percentage of cells with fragmentated mitochondria. This method
shows an increased percentage of cells with fragmented mitochondria (A-B). The same
experiments were repeated but were quantified using the author’s novel method, and the results
show an increased number of mitochondrial fragments per cell (C-D). The parallel results
validate the author’s novel method as a less time-consuming and more quantitative means of
quantifying mitochondrial fragmentation.
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CHAPTER 2- CELL VIABILITY AND MITOCHONDRIAL MORPHOLOGY IN SUB-ACUTE AND
CHRONIC MODELS OF FRIEDREICH ATAXIA

2.1 Abstract

The progressive nature of FRDA inherently suggests that pathologies may differ across
different stages of disease. Cells in early stages of disease progression may exhibit drastically
different phenotypes from those in later stages. It therefore becomes critical to compare subacute and chronic models of FRDA to gain insights into differential pathway expression across
disease progression.
Numerous neurodegenerative disease models exhibit excessive mitochondrial
fragmentation; additionally, a yeast model of FRDA also exhibits fragmentated mitochondria 117.
However, mitochondrial fragmentation has not previously been investigated across sub-acute and
chronic models of FRDA in human fibroblasts. Moreover, mitochondrial fragmentation has not
previously been causally linked to FXN deficiency through knockout/restoration experiments.
The goal of this chapter is to demonstrate the effects of sub-acute and chronic FXN
deficiency on mitochondrial fragmentation in human cells. To begin a pathway analysis and
investigate the effects on metabolism, this chapter also examines the effects of sub-acute and
chronic FXN deficiency on levels of proteins relevant to this area of investigation as well as the
effects on overall ATP levels. The results of these experiments begin to reveal the relationship
between FXN deficiency, mitochondrial fragmentation, and ATP levels in sub-acute and chronic
models of FRDA.

2.2. Introduction
FXN is differentially expressed in a tissue-specific manner during development, with the
highest levels in the spinal cord and dorsal root ganglia 118. That FXN deficiency in FRDA
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drastically impacts these tissues is therefore unsurprising; however, this observation during
development additionally speaks to the progressive nature of FRDA. The prenatal impacts of
such dysregulated protein expression alter development, and the disease progressively
intensifies throughout the course of a patient’s life119,120. Therefore, investigating both the
immediate response and the long-term effects of FXN deficiency is critical to understanding the
molecular response to this insult. This dissertation thus utilizes both sub-acute and chronic
models of FRDA to differentiate between the initial response to FXN deficiency and the pathway
alterations resulting from the chronic disease.
To examine the cell’s immediate response to FXN loss, siRNA-mediated FXN knockdown
provides an invaluable tool. Examining how the cell responds to this insult reveals the
homeostatic mechanisms the cell utilizes in an attempt to accommodate for this stress. In
addition to providing increased understanding of FXN’s role in cellular functions, this model may
also reveal potential therapeutic targets for FRDA.
Contrast this sub-acute model to FRDA patient-derived fibroblasts; in this model cells
exhibit chronic FXN deficiency in the same capacity as patients by the time the present at clinic.
Fibroblasts provide a relatively non-invasive method for studying patient-derived tissue.
Investigating these cells may reveal the long-term alterations to molecular pathways that result
from the cell attempting to maintain homeostasis throughout the chronic insult of FRDA.
Transfecting FRDA patient-derived fibroblasts with exogenous FXN then demonstrates which
cellular phenotypes may be reversed by restoring FXN levels. While certain disease phenotypes
may be reversed by FXN re-expression, other pathways may be too drastically altered such that
FXN restoration is incapable of restoring the healthy phenotype.
The results of FXN knockdown in conjunction with the results of FXN re-expression
provide further insight into the disease pathologies that are dependent upon FXN levels. The
combination of these results may demonstrate which pathway dysregulations are directly caused
by FXN deficiency. Comparing these results to those from the patient-derived fibroblasts
provides insight into which mechanisms represent an initial response to the insult of FXN loss and
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which mechanisms are long-term consequences and alterations resulting from chronic FXN
deficiency.
While fibroblasts provide an efficient and valuable model for studying these pathway
alterations, limitations exist that are inherent to in vitro experiments. The cell culture environment
does not fully imitate the environment of cells in the body. Interactions with other tissue types
may alter the cellular response to sub-acute and chronic FXN deficiency as well as FXN
restoration. Thus, the results of in vitro models may not be extrapolated to the organismal level.
Additionally, fibroblasts are only one tissue type while FRDA is a multi-system disorder. The
results from fibroblasts may not necessarily be consistent throughout all tissue types. Despite
these limitations, these fibroblast models do provide critical information on cellular responses in
FRDA. The data gathered from such in vitro experiments may later guide work in vivo.
This chapter thus incorporates sub-acute, chronic, and FXN restoration models of FRDA
to differentiate between these molecular alterations. It investigates protein levels, ATP levels, the
amount of mitochondrial fragmentation, and the amount of (Ser616) phospho-Drp1 clusters as
biomarkers of disease state and differential pathway regulation in each model.

2.3 Frataxin knockdown
To determine the effects of sub-acute FXN deficiency on mitochondrial morphology and
function, fibroblasts derived from healthy individuals were transfected with siRNA targeted to
FXN. This siRNA-mediated FXN knockdown resulted in 0.36 times the level of FXN observed in
fibroblasts transfected with an empty vector (Fig. 2.3.1). FXN knockdown in this model did not
alter the total levels of Drp1 or (Ser616) phospho-Drp1 protein (Fig. 2.3.2); however, the level of
Mc1 was significantly increased to 3.9 times the level in controls (Fig. 2.3.3). FXN knockdown
significantly increased the number of mitochondrial fragments (Fig. 2.3.4) and (Ser616) phosphoDrp1 clustering (Fig. 2.3.5) per cell. ATP levels were unaffected by FXN knockdown (Fig. 2.3.6).
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Fig. 2.3.1 Validation of siRNA-mediated frataxin knockdown in fibroblasts derived from a healthy
control individual. Representative Western blot of healthy fibroblasts transfected with FXNtargeted siRNA or a non-targeting siRNA control (A). FXN levels were decreased to 36% of
control levels (B). *p<0.05, Wilcoxon rank-sum test. n=3.

Fig. 2.3.2 Frataxin knockdown does not significantly alter Drp1 or (S616) phospho-Drp1 protein
levels. Representative Western blot healthy fibroblasts transfected with FXN-targeted siRNA or a
non-targeting siRNA control (A). FXN knockdown did not significantly alter the overall levels of
(Ser616) phospho-Drp1 or Drp1 (B). n.s. not significant, Wilcoxon rank-sum test. n=3.
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Fig. 2.3.3 Frataxin knockdown significantly increases the level of Mcl1. Representative Western
blot of healthy fibroblasts transfected with FXN-targeted siRNA or a non-targeting siRNA control
(A). FXN was decreased to 20% of control, and Mcl1 were increased to 390% of control (B).
*p<0.05, **p<0.01, Wilcoxon rank-sum test. n=3.

23

Fig. 2.3.4 FXN knockdown significantly increases the percentage of cells with fragmented
mitochondria. ICC of a mitochondrial marker in healthy fibroblasts transfected with a nontargeting siRNA (A) or FXN-targeted siRNA (B). FXN knockdown increased the percentage of
cells with fragmented mitochondria (41.2% vs 91.0%) (C). **p<0.01, two-sided t-test. n=3
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Fig. 2.3.5 Frataxin knockdown increases the number of mitochondrial fragments per cell. ICC of
a mitochondrial marker in healthy fibroblasts transfected with a non-targeting siRNA (A) or FXNtargeted siRNA (B). FXN knockdown increased the number of mitochondrial fragments per cell
from 1225 to 2135 (C). **p<0.01, two-sided t-test. n=6.
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Fig. 2.3.6 Frataxin knockdown increases the number of (Ser616) phospho-Drp1 clusters per cell.
ICC of (Ser616) phospho-Drp1 in healthy fibroblasts transfected with a non-targeting siRNA (A) or
FXN-targeted siRNA (B). FXN knockdown increased the number of (Ser616) phospho-Drp1
clusters per cell from 758 to 1790 (C). *p<0.05, two-sided t-test. n=6
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Fig. 2.3.6 Frataxin knockdown does not alter ATP levels. A luminescence-based assay to
quantify the relative amount of ATP in cells reveals that FXN knockdown did not significantly alter
ATP levels (A). n. s. not significant, two-sided t-test. n=3.

2.4 Patient-derived cells
The results of sub-acute FXN deficiency were then compared to those of chronic FXN
deficiency. Fibroblasts derived from 3 individual FRDA patients exhibited 0.17 times the level of
FXN observed in fibroblasts derived from a healthy individual (Fig. 2.4.1). The total levels of Drp1
and (Ser616) phospho-Drp1 protein were unaffected (Fig. 2.4.2). The levels of FXN RNA
transcripts were significantly decreased and CDK1 transcripts were significantly increased, while
the levels of Drp1 and Mcl1 transcripts were unchanged (Fig. 2.4.3). A significantly higher
percentage of FRDA patient fibroblasts exhibited fragmented mitochondria compared to healthy
fibroblasts (Fig. 2.4.4). The FRDA patient-derived fibroblasts exhibited significantly increased
mitochondrial fragmentation (Fig. 2.4.5) and significantly increased (Ser616) phospho-Drp1
clustering (Fig. 2.4.6) per cell. These patient-derived fibroblasts exhibited significantly decreased
levels of ATP compared to healthy control fibroblasts (Fig. 2.4.7).
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Fig. 2.4.1 FRDA patient fibroblasts have lower levels of FXN than healthy controls.
Representative Western blot of FRDA patient-derived fibroblasts (A). FRDA patient-derived
fibroblasts exhibited 17% the level of FXN in healthy control fibroblasts (B). *p<0.05, Wilcoxon
rank-sum test. n=5 biological replicates.

Fig. 2.4.2 FRDA patient fibroblasts do not have significantly altered levels of Drp1 or (Ser616)
phospho-Drp1 protein. Representative Western blot of FRDA patient-derived fibroblasts (A).
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FRDA patient-derived fibroblasts did not exhibit significantly altered levels of (Ser616) phosphoDrp1 or Drp1. n.s. not significant, Wilcoxon rank-sum test. n=5 biological replicates.

Fig. 2.4.3 Alterations to gene transcripts for proteins that regulate mitochondrial morphology.
These data are derived from the normalized levels of mRNA transcripts. FRDA patient cells
exhibit significantly decreased FXN transcripts (43.7% of healthy controls, A). Drp1 transcript
levels were not significantly altered (B). CDK1 transcript levels were significantly increased to
364.4% the levels observed in healthy controls (C). Mcl1 transcript levels were not significantly
altered (D). n. s. not significant, *p<0.05, **p<0.01, two-sided t-test.
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Fig. 2.4.4 A significantly higher proportion of FRDA patient-derived fibroblasts compared to
healthy controls. ICC of a mitochondrial marker in healthy control fibroblasts (A) or FRDA patientderived fibroblasts (B). While 9.8% of healthy control fibroblasts exhibited fragmented
mitochondria, 44.8% of FRDA patient-derived fibroblasts exhibited fragmented mitochondria (C).
**p<0.01, two-sided t-test. n=4 technical replicates for each of 3 biological replicates.
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Fig. 2.4.5 FRDA patient fibroblasts have significantly increased mitochondrial fragments per cell
compared to healthy controls. ICC of a mitochondrial marker in healthy control fibroblasts (A) or
FRDA patient-derived fibroblasts (B). While controls exhibited 182 mitochondrial fragments per
cell, FRDA patient-derived fibroblasts exhibit 580 fragments per cell (C). *p<0.05, two-sided ttest. n=2 technical replicates for each of 3 biological replicates.
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Fig. 2.4.6 FRDA patient fibroblasts have significantly increased (Ser616) phospho-Drp1 clusters
per cell compared to healthy controls. ICC of (Ser616) phospho-Drp1 in healthy control
fibroblasts (A) or FRDA patient-derived fibroblasts (B). While controls exhibited 828 (Ser616)
phospho-Drp1 clusters per cell, FRDA patient-derived fibroblasts exhibited1448 clusters per cell
(C). *p<0.05, two-sided t-test. n=2 technical replicates for each of 3 biological replicates.
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Fig. 2.4.7 FRDA patient fibroblasts have significantly decreased levels of ATP compared to
healthy controls. A luminescence-based assay to quantify the relative amount of ATP in cells
reveals that FRDA patient-derived fibroblasts exhibited 90% the level of ATP in healthy controls
(A). *p<0.05, two-sided t-test. n=2 technical replicates for each of 5 biological replicates.
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2.5 Exogenous frataxin overexpression
To determine whether the effects of chronic FXN deficiency are reversible and directly
dependent upon FXN expression, 3 FRDA patient-derived fibroblast lines were transfected with a
plasmid encoding FXN. This transfection resulted in FXN expression at 260% observed in FRDA
patient fibroblasts transfected with an empty vector (Fig. 2.4.1). FXN overexpression did not alter
the total levels of Drp1 or (Ser616) phospho-Drp1 protein (Fig. 2.4.2), but it significantly
decreased both mitochondrial fragmentation (Fig. 2.4.3) and (Ser616) phospho-Drp1 clustering
(Fig. 2.4.4) per cell. However, FXN overexpression did not affect ATP levels (Fig. 2.4.5)

Fig. 2.5.1 Validation of FXN transfection and overexpression. Representative Western blot of
FRDA patient-derived fibroblasts transfected with either an empty vector or a plasmid encoding
human FXN (A). Transfection increased FXN expression to 260% of the vector control (B).
*p<0.05, Wilcoxon rank-sum test. n=5 biological replicates.
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Fig. 2.5.2 Frataxin overexpression does not affect the levels of Drp1 or (Ser616) phospho-Drp1.
Representative Western blot of FRDA patient-derived fibroblasts transfected with either an empty
vector or a plasmid encoding human FXN (A). FXN transfection does not significantly alter the
levels of (Ser616) phospho-Drp1 or Drp1 (B). n.s. not significant, Wilcoxon rank-sum test. n=5
biological replicates.
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Fig. 2.5.3 Frataxin overexpression decreases the number of mitochondrial fragments per cell in
FRDA patient-derived fibroblasts. ICC of a mitochondrial marker in FRDA patient-derived
fibroblasts transfected with an empty vector (A) or a plasmid encoding FXN (B). FXN transfection
decreased the number of mitochondrial fragments per cell from 594 to 335 (C). **p<0.01, twosided t-test. n=2 technical replicates for each of 3 biological replicates.
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Fig. 2.5.4 Frataxin overexpression decreases the number of (Ser616) phospho-Drp1 clusters per
cell in FRDA patient-derived fibroblasts. ICC of a (Ser616) phospho-Drp1 in FRDA patientderived fibroblasts transfected with an empty vector (A) or a plasmid encoding FXN (B). FXN
transfection decreased the number of (Ser616) phospho-Drp1 clusters per cell from 2261 to 856
(C). ***p<0.001, two-sided t-test. n=2 technical replicates for each of 3 biological replicates.
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Fig. 2.5.5 Frataxin overexpression does not affect the level of ATP in FRDA patient-derived
fibroblasts. A luminescence-based assay to quantify the relative amount of ATP in cells reveals
that FXN transfection did not significantly alter ATP levels in FRDA patient-derived fibroblasts (A).
n.s. not significant, two-sided t-test. n=2 technical replicates for each of 5 biological replicates.
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2.6 Discussion

Mitochondrial fragmentation is significantly increased within 72 hours of FXN knockdown
in healthy fibroblasts, suggesting that this mechanism responds rapidly to FXN deficiency.
Moreover, it reveals that fragmentation is a direct response to FXN deficiency, rather than a
response to alterations in other pathways that may occur during chronic FXN deficiency. While
FXN knockdown does not alter the overall levels of (Ser616) phospho-Drp1 or Drp1, the number
of (Ser616) phospho-Drp1 clusters is significantly increased. It is possible that the rate of
turnover for this protein is longer, so an extended time course may reveal differences in the
overall levels of these proteins. The initial response, however, appears dependent upon (Ser616)
phospho-Drp1 oligomerization and localization to the mitochondria. In addition to the increased
number of (Ser616) phospho-Drp1 clusters, this idea is further supported by the increased levels
of Mcl1, the protein that chaperones (Ser616) phospho-Drp1 to the mitochondria. FXN
knockdown, however, does not alter the level of ATP. It is conceivable that fibroblasts are initially
able to cope with FXN deficiency such that ATP levels remain unchanged. Mitochondrial
fragmentation, which increases the mitochondrial surface area, may represent an adaptive,
homeostatic mechanism in FRDA by which cells maintain ATP levels; further evidence for this
hypothesis will be discussed in Chapter 3.
The standard method for the field to quantify mitochondrial fragmentation involves a
blinded individual counting the number of cells that appear to exhibit tubular or fragmented
mitochondria. Indeed, a significantly higher percentage of FRDA patient-derived fibroblasts
exhibit fragmented mitochondria compared to healthy controls (Fig. 2.3.4 and 2.4.4). The
author’s novel method for quantifying mitochondrial fragmentation in a more quantitative and
reproducible manner achieves similar results, with FRDA patient derived fibroblasts exhibiting an
increased number of mitochondrial fragments per cell compared to healthy controls (Fig. 2.3.5
and 2.4.5). The parallel between these results validates this novel method as an effective and
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reliable means to quantify mitochondrial fragmentation, and this method will be used throughout
the succeeding chapters due to its increased rigor and reproducibility.
GRP75 (Hsp70) immunostaining provided higher resolution images of the mitochondria
than other mitochondrial markers (preliminary data, not shown). This protein predominantly
localizes to the mitochondria, making it a useful mitochondrial marker 121-123. However, some
evidence suggests that a percentage of GRP75 also localizes to other sub-cellular
compartments124. Because it primarily localizes to the mitochondria, the immunofluorescence
signal from mitochondrial GRP75 would be more intense than the signal from extramitochondrial
copies of the protein; as such, the low immunofluorescence signaling resulting from
extramitochondrial GRP75 was eliminated by setting a minimum signal threshold before
quantifying the number of mitochondrial fragments per cell.
Chronic FXN deficiency as observed in FRDA patient-derived fibroblasts results in similar
phenotypes to those exhibited during sub-acute FXN deficiency. Mitochondrial fragmentation is
increased while the levels of (Ser616) phospho-Drp1 and Drp1 are unaltered. Additionally, Drp1
transcript levels are unchanged in FRDA patient derived fibroblasts while CDK1 transcript levels
are significantly increased. Since CDK1 phosphorylates Drp1 at Ser616, this may represent a
potential mechanism by which Drp1 is activated in FRDA. As Mcl1 chaperones (Ser616)
phospho-Drp1 to the mitochondria, this protein may represent another mechanism by which
mitochondrial fragmentation occurs in FRDA. Mcl1 protein levels are increased in FXN
knockdown fibroblasts; however, the transcript levels are unchanged in FRDA patient fibroblasts.
This may represent a difference between sub-acute and chronic FRDA models; moreover, it is
conceivable that Mcl1 levels and/or activity are altered post-transcriptionally. Additionally, the
level of ATP in FRDA patient-derived fibroblasts is significantly lower than in control fibroblasts,
suggesting that these cells may initially be able to cope with FXN deficiency but become less
capable of doing so in a chronic state.
Exogenous FXN expression in FRDA patient-derived fibroblasts largely rescues the
abnormal mitochondrial phenotypes they express; the number of mitochondrial fragments and
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(Ser616) phospho-Drp1 clusters per cell are significantly decreased. This provides further
evidence that mitochondrial fragmentation in FRDA is directly dependent upon FXN expression
levels. However, FXN expression does not restore ATP levels in these patient-derived
fibroblasts. It is possible that these cells utilize FXN-independent pathways to generate ATP.
While such an approach is not quite as effective as FXN-dependent pathways, as demonstrated
by the significantly lower ATP levels in patient cells, increased utilization of such pathways may
represent a mechanism by which the cells adapt to FXN deficiency. As the cells rely less upon
FXN-dependent pathways, re-expression of FXN does not alter ATP levels. It is possible that
FXN transfection over a longer time course may cause the cells to revert to FXN-dependent
mechanisms for ATP synthesis, resulting in increased ATP levels; alternatively, the chronic FXN
deficiency may drive the cells into a relatively irreversible state of FXN-independent ATP
synthesis such that FXN expression may not improve cellular bioenergetics regardless of the time
course.
The lack of increased ATP synthesis in FRDA patient-derived cells with FXN transfection
has critical implications for gene therapy approaches to treating FRDA. A current investigation
includes administering a FXN-encoding plasmid to the KIKO model through intravenous and/or
intracerebroventricular injections. Even if such an approach restores FXN levels in critical tissues
like the cerebellum, however, it remains unproven whether FXN expression in FRDA patients will
provide any benefit. Moreover, the level of FXN protein re-expression resulting from such gene
therapy may impact the cellular and organismal responses. Further investigation of the potential
benefits, or lack thereof, of FXN re-expression in FRDA models should be conducted before
continuing to pursue gene therapy as a course of treatment.
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CHAPTER 3- EFFECTS OF TAT-P110 ON MITOCHONDRIAL MORPHOLOGY AND CELL
VIABILITY IN FRIEDREICH ATAXIA MODELS

3.1 Abstract
The GTPase Drp1 execute mitochondrial fragmentation; when phosphorylated at its
(Ser616) residue, Drp1 is recruited to MAM’s by Mcl1, oligomerizes into clusters, and
mechanically severs the mitochondria. To determine whether mitochondrial fragmentation in
FRDA is dependent upon Drp1 activity, sub-acute and chronic models of FRDA were treated with
a Drp1 inhibitor, and the relevant outcome measures were quantified similarly to Chapter 2.
P110 is small peptide that inhibits (Ser616) phospho-Drp1 from binding to the
mitochondria. In several neurodegenerative and cardiomyopathy disease models, treatment with
this peptide reverses mitochondrial fragmentation and improves cellular bioenergetics 71-73,75,76.
To improve cellular uptake, a cell-penetrating TAT domain may be added to the N-terminus of
P11072. The effects of this drug on sub-acute and chronic FRDA models have not previously
been studied.
The goal of this chapter is to determine whether mitochondrial fragmentation in FRDA is
dependent upon Drp1 activity. Moreover, this chapter will explore whether mitochondrial
fragmentation represents a beneficial, homeostatic mechanism or a maladaptive mechanism in
FRDA. This chapter will begin to investigate the pathway by which FXN deficiency may cause
mitochondrial fragmentation and will explore whether mitochondrial fragmentation represents a
viable therapeutic target in FRDA.

3.2 Introduction
Chapter 2 established that FXN deficiency causes excessive mitochondrial fragmentation
in FRDA, likely through increasing (Ser616) phospho-Drp1 localization to the mitochondria by
upregulating the chaperone protein Mcl1. While it establishes a correlation between increased
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(Ser616) phospho-Drp1 clustering and increased mitochondrial fragmentation in FRDA, the data
in Chapter 2 do not establish a causative link between these observations. The goal of Chapter 3
is to determine whether mitochondrial fragmentation in FRDA is dependent upon Drp1 activity.
Drp1 inhibition in sub-acute and chronic FRDA models provides a valuable tool for
elucidating this pathway. The small peptide mdivi-1 had previously been widely utilized as a
mitochondrial fission inhibitor; however, although this peptide inhibits the GTPase activity of Drp1,
it also inhibits Bax-mediated permeabilization of the OMM, thereby preventing cytochrome c
release125. While mdivi-1 is more selective than a previous inhibitor of mitochondrial
fragmentation126, a Drp1 inhibitor that is more selective than mdivi-1 has since replaced this drug
in pathway analysis experiments. P110 selectively inhibits the GTPase activity of Drp1 and
prevents Drp1 from binding to Fis1, thus preventing Drp1 from binding to and severing the
mitochondria70. To investigate the pathway by which FXN deficiency cause mitochondrial
fragmentation in FA, P110 serves as a valuable tool due to its high selectivity for Drp1.
Furthermore, P110, sometimes fused to the cell-penetrating TAT sequence on its Nterminus, provides bioenergetic benefits in several neurodegenerative disease models 71-74. This
drug may increase ATP synthesis as well as ameliorate ROS accumulation in these models. To
determine whether TAT-P110 could likewise provide these benefits in FRDA, sub-acute and
chronic models of FRDA were treated with this drug. Following treatment, the levels of relevant
proteins, ATP levels, the amount of mitochondrial fragmentation, and the number of (Ser616)
phospho-Drp1 clusters were quantified. These experiments may thus provide insight as to
whether mitochondrial fragmentation in FRDA is dependent upon Drp1 activity and whether
mitochondrial fragmentation represents a homeostatic or a maladaptive mechanism in this
disease.

3.3 Frataxin knockdown with TAT-P110
To determine the effects of Drp1 inhibition on sub-acute FXN deficiency, healthy control
fibroblasts were transfected with FXN-targeted siRNA and treated with 1 µM TAT-P110 for 72
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hours. TAT-P110 did not alter the level of FXN in healthy fibroblasts transfected with siRNA
targeting FXN (Fig. 3.3.1). This drug significantly decreased the number of mitochondrial
fragments (Fig. 3.3.2) as well as (Ser616) phospho-Drp1 clusters (Fig. 3.3.3) in these FXN
knockdown cells. The overall levels of Drp1 and (Ser616) phospho-Drp1, however, were
unaffected (Fig. 3.3.4). Preventing mitochondrial fragmentation in FXN knockdown fibroblasts
using TAT-P110 significantly decreased the level of ATP in these cells (Fig. 3.3.5).

Fig. 3.3.1. TAT-P110 does not alter the level of FXN in healthy fibroblasts transfected with FXNtargeted siRNA. Representative Western blot of healthy fibroblasts transfected with FXNtargeted siRNA and treated with 1 µM TAT-P110 or an inactive control peptide (Scrambled TATP110) for 72 hours (A). The Drp1 inhibitor did not alter the level of FXN (B). n.s. not significant,
Wilcoxon rank-sum test. n=3.
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Fig. 3.3.2 TAT-P110 does not alter the overall levels of Drp1 or (Ser616) phospho-Drp1 in healthy
fibroblasts transfected with FXN-targeted siRNA. Representative Western blot of healthy
fibroblasts transfected with FXN-targeted siRNA and treated with 1 µM TAT-P110 or an inactive
control peptide (Scrambled TAT-P110) for 72 hours (A). The Drp1 inhibitor did not alter the levels
of (Ser616) phospho-Drp1 or Drp1 (B). n.s. not significant, Wilcoxon sum-rank test. n=3.
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Fig. 3.3.3 TAT-P110 significantly decreases the number of mitochondrial fragments per cell
resulting from FXN knockdown in healthy fibroblasts. ICC for a mitochondrial marker in FXNknockdown fibroblasts treated with 1 µM of an inactive control peptide (scrambled TAT-P110, A)
or TAT-P110 (B) for 72 hours. The Drp1 inhibitor significantly decreased the number of
mitochondrial fragments per cell from 284 to 164. *p<0.05, two-sided t-test. n=5.

46

Fig. 3.3.4 TAT-P110 significantly decreases the number of (Ser616) phospho-Drp1 clusters per
cell resulting from FXN knockdown in healthy fibroblasts. ICC for (Ser616) phospho-Drp1 in
FXN-knockdown fibroblasts treated with 1 µM of an inactive control peptide (scrambled TATP110, A) or TAT-P110 (B) for 72 hours. The Drp1 inhibitor significantly decreased the number of
(Ser616) phospho-Drp1 clusters per cell from 1208 to 872. *p<0.05, two-sided t-test.
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Fig. 3.3.5 TAT-P110 significantly decreases the level of ATP in FXN knockdown fibroblasts. A
luminescence-based assay performed on FXN knockdown fibroblasts reveals that TAT-P110
significantly decreased ATP levels to 64% of those in controls (A). **p<0.01, Wilcoxon rank-sum
test. n=3.

3.4 Patient-derived cells with TAT-P110

To investigate the effects of Drp1 inhibition on chronic FXN deficiency, 2 FRDA patientderived fibroblast cell lines were treated with 1 µM of an inactive control peptide (scrambled TATP110) or TAT-P110 for 72 hours. At this time course and concentration, TAT-P110 did not
significantly impact the levels of FXN, Drp1, or (Ser616) phospho-Drp1 in FRDA patient-derived
fibroblasts (Fig. 3.4.1 and Fig. 3.4.2). TAT-P110 treatment resulted in an insignificant trend
toward decreasing the number of mitochondrial fragments per cell (Fig. 3.4.3), and significantly
decreased the number of (Ser616) phospho-Drp1 clusters per cell (Fig. 3.4.4). Moreover, TATP110 treatment resulted in an insignificant trend toward decreasing the ATP levels in FRDApatient derived fibroblasts (Fig. 3.4.5).
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Fig. 3.4.1 TAT-P110 does not alter the level of FXN in FRDA patient-derived fibroblasts.
Representative Western blot of FRDA patient-derived fibroblasts treated with 1µM TAT-P110 or
inactive control peptide (scrambled TAT-P110 for 72 hours (A). The Drp1 inhibitor did not
significantly alter the level of FXN (B). n.s. not significant, Wilcoxon sum-rank test. n=5 biological
replicates.
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Fig. 3.4.2 TAT-P110 does not alter the overall levels of Drp1 or (Ser616) phospho-Drp1 in FRDA
patient-derived fibroblasts. Representative Western blot of FRDA patient-derived fibroblasts
treated with 1µM TAT-P110 or inactive control peptide (scrambled TAT-P110 for 72 hours (A).
The Drp1 inhibitor did not significantly alter the levels of (Ser616) phospho-Drp1 or Drp1 (B). n.s.
not significant, Wilcoxon sum-rank test. n=5 biological replicates.

Fig. 3.4.3 TAT-P110 trends toward decreasing the number of mitochondrial fragments per cell in
FRDA patient-derived fibroblasts. ICC of a mitochondrial marker for FRDA patient-derived
fibroblasts treated with an inactive control peptide (scrambled TAT-P110, A) or 1µM TAT-P110
(B) for 72 hours. The Drp1 inhibitor did not significantly alter the number of mitochondrial
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fragments per cell (C). n. s. not significant, two-sided t-test. n=3 technical replicates for each of 2
biological replicates.

Fig. 3.4.4 TAT-P110 significantly decreases the number of (Ser616) phospho-Drp1 clusters per
cell in FRDA patient-derived fibroblasts. ICC of (Ser616) phospho-Drp1 for FRDA patient-derived
fibroblasts treated with an inactive control peptide (scrambled TAT-P110, A) or 1µM TAT-P110
(B) for 72 hours. The Drp1 inhibitor significantly decreased the number of (Ser616) phosho-Drp1
clusters per cell from 3476 to 2095 (C). *p<0.05, two-sided t-test. n=3 technical replicates for
each of 2 biological replicates.
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Fig. 3.4.5 TAT-P110 trends toward decreasing ATP levels in FRDA patient-derived fibroblasts. A
luminescence-based assay performed on FXN knockdown fibroblasts reveals that TAT-P110 did
not significantly alter ATP levels in FRDA patient-derived fibroblasts (A). n. s. not significant,
Wilcoxon rank-sum test. m=2 technical replicates for each of 5 biological replicates.

3.5 Discussion
Treatment with 500 nM to 1 µM of P110 appears to provide the maximal benefits in other
disease models71-74, so the FRDA models were treated with 1 µM of this drug; in the FXN
knockdown model, drug treatment occurred simultaneously with siRNA transfection. The 72-hour
time course was selected because at this time point following siRNA transfection, the levels of
FXN in the knockdown model are approximately equivalent to the FXN levels in the FRDA
patient-derived fibroblasts. This allows for a reasonable comparison between the two models to
parse the differences between the cellular response to TAT-P110 at the sub-acute and chronic
stages of FXN deficiency.
TAT-P110 does not alter the levels of FXN, (Ser616) phospho-Drp1, or Drp1 in FXN
knockdown fibroblasts. As this drug inhibits the GTPase activity of Drp1 and prevents it from
binding to the mitochondria, it is unsurprising that the level of Drp1 is unaffected within 72 hours
of treatment. The number of (Ser616) phospho-Drp1 clusters is significantly decreased, which is
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indicative of the drug’s mechanism of action. TAT-P110 significantly decreases the number of
mitochondrial fragments per cell; this drug specifically inhibits Drp1 activity, suggesting that FXNdeficiency-induced mitochondrial fragmentation is dependent upon Drp1 activity. In neither the
sub-acute nor the chronic model does Drp1 inhibition alter the level of FXN, suggesting that
mitochondrial fragmentation is a downstream event of FXN deficiency; while restoring FXN levels
reverses mitochondrial fragmentation (see Chapter 2), reversing mitochondrial fragmentation
does not restore FXN levels.
TAT-P110 significantly decreases the level of ATP in FXN-knockdown fibroblast.
Because this Drp1 inhibitor both prevents mitochondrial fragmentation and decreases ATP levels,
mitochondrial fragmentation appears to be an adaptive, homeostatic mechanism in FRDA that
allows cells to initially cope with FXN deficiency. Compare this result to the effects of P110 in
other neurodegenerative diseases; in models of AD, PD, MS, and HD, Drp1 inhibition both
reversed mitochondrial fragmentation and improved cellular respiration71-74,127. In these diseases,
mitochondrial dysfunction appears to be a secondary feature of the disease, far downstream of
the factor that causes the disease. Mitochondrial fragmentation in these diseases, then, appears
to be a maladaptive mechanism, and as such, reversing fragmentation may prove beneficial for
the cell. Contrarily, mitochondrial dysfunction is a primary feature of FRDA, a direct consequence
of FXN deficiency. This suggests that mitochondrial fragmentation is an adaptive mechanism in
FRDA that allows the cells to maintain ATP synthesis initially after the insult of FXN deficiency.
Therefore, unlike several other neurodegenerative disease, mitochondrial fragmentation does not
appear to be a viable therapeutic target for FRDA.
In FRDA patient-derived fibroblasts, TAT-P110 is less effective than in FXN-knockdown
fibroblasts. The Drp1 inhibitor still significantly decreases the number of (Ser616) phospho-Drp1
clusters, which is indicative of the drugs activity, but it only trends toward decreasing the number
of mitochondrial fragments per cell; similarly, this drug trends toward decreasing the cellular
levels of ATP. First, these results are indicative of the inherent differences between sub-acute
and chronic models of disease: cells remain malleable for some time after an initial insult, but as
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the cells enter a chronic stage of disease, other adaptations are strongly expressed such that
they are less capable of being altered. It is possible that the cells require a longer time course to
exhibit further changes. Second, both the number of mitochondrial fragments per cell and the
cellular level of ATP trend toward a decrease in FRDA patient fibroblasts. This suggests that a
correlation may exist between the amount of mitochondrial fragmentation and the cell’s ability to
generate ATP, further suggesting that mitochondrial fragmentation is a homeostatic mechanism,
both acutely and chronically, in FRDA.
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CHAPTER 4- EFFECTS OF SS-31 ON MITOCHONDRIAL MORPHOLOGY AND CELL
VIABILITY IN FRIDREICH ATAXIA MODELS

4.1 Abstract
SS-31 is a small peptide that stabilizes cardiolipin (CL), a four-tailed phospholipid critical
for cristae formation on the IMM and for anchoring the ETC complexes 77. Oxidation of CL results
in cytochrome c release and impaired ETC function, leading to decreased ATP synthesis. SS-31
is thought to stabilize the electrostatic interactions between CL and these various IMM proteins as
well as inhibit CL oxidation. This peptide reverses mitochondrial fragmentation and improves
bioenergetics, in several neurodegenerative disease models82,84,85,128. Additionally, this peptide
reverses mitochondrial fragmentation in one FRDA patient-derived lymphoblast cell line87.
However, as individual patients or tissue types may respond differently to a given drug, it is
necessary to study the effects of SS-31 on cell lines derived from multiple patients and from
different tissue types. Additionally, the effects of SS-31 on an in vivo model of FRDA have not
previously been investigated.
The goal of this chapter is to identify the effects of SS-31 on FXN and Drp1 protein levels
in vivo. Additionally, this chapter explores the effects of SS-31 on up to 5 FRDA patient-derived
fibroblasts lines, offering a more comprehensive study of this peptide’s effects to account for
variability across individuals. The effects of SS-31 on mitochondrial fragmentation, protein levels,
and ATP levels are investigated. Furthermore, a comparison between SS-31 and TAT-P110 is
performed. FRDA patient-derived fibroblasts are treated with both drugs simultaneously to
determine whether the effects of the drugs are additive. This provides insight into the
mechanisms of action of these drugs, suggesting that they exert their effects at different points
along the same pathway leading to mitochondrial fragmentation.
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4.2 Introduction
Cardiolipin is a four-tailed fatty acid derivative of phosphatidic acid78. The unusual fourtailed structure of CL allows this phospholipid to play a critical role in maintaining membrane
morphology81. While CL primarily localizes to the inner mitochondrial membrane (IMM), this
phospholipid may also localize to the outer mitochondrial membrane (OMM) where it contributes
to regulating mitochondrial dynamics78,81,129,130. Due to its unique four-tailed structure, CL is
critical for cristae formation on the IMM78,81. Additionally, CL anchors the electron transport chain
(ETC) complexes to the IMM and brings these complexes in close proximity to one another,
optimizing ETC functioning78. Moreover, electrostatic interactions between CL and cytochrome c
inhibit cytochrome c release from the mitochondria, thereby preventing this apoptosis signaling
mechanism80,131. However, when these electrostatic interactions are disrupted (e.g. through
cellular accumulation of ROS), cytochrome c is released from the mitochondria, resulting in
apoptosis signaling79,80,131. Due to these critical functions in bioenergetics, mitochondrial
dynamics, and apoptosis, CL deficiency has severe pathophysiological implications. For
instance, Barth syndrome results from a mutation in the tafazzin gene which encodes a
transacylase that facilitates CL remodeling during its conversion from phosphatidic acid 132,133.
Certain features of Barth syndrome, including mitochondrial dysfunction, cardiomyopathy, and
increased susceptibility to fatigue, parallel features of FRDA 132-134. The parallels between the CLdeficiency disease Barth syndrome and FRDA provide a rationale for studying the role of CL in
FRDA. Therefore, it is reasonable to investigate the potential therapeutic benefits of targeting CL
in FRDA.
Szeto-Schiller compound 31 (SS-31) targets CL, potentially protecting the electrostatic
interactions between CL and other mitochondrial proteins from disruption by ROS77. The
therapeutic effects of this compound have been investigated in several neurodegenerative and
cardiomyopathy disease models, including a study in one FRDA lymphoblast cell line82-85,87,128,135.
SS-31 improves bioenergetics, ameliorates the effects of oxidative damage, and reverses
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mitochondrial fragmentation in numerous disease models82-85,87,128,135. SS-31 reverses
mitochondrial fragmentation and increases FXN levels in one FRDA patient-derived lymphoblast
line87.
While in vitro diseases models, like the sub-acute and chronic fibroblast models of FRDA
provide valuable tools for pathway analysis and drug mechanism of action studies, such models
have limitations. Cell cultures do not accurately represent the organismal environment.
Interactions across tissue types may alter the cellular response to drugs, and in vitro results do
not necessarily transfer directly to in vivo models or to humans. In vivo experiments, while still
not fully reflective of humans, may supplement in vitro data by offering a comparison between
cellular and organismal level data. Therefore, Chapter 4 employs both in vitro and in vivo models
to examine the effects of SS-31. The Knock-in/Knockout (KIKO) mouse model of FRDA (Jackson
Laboratories #012329 B6.Cg-Fxn(tm1.1Pand) Fxn(tm1Mkn/J)) contains a null mutation on one
FXN allele and a humanized expansion sequence on the second FXN allele . In addition to FXN
deficiency, this mouse also presents certain molecular and neurobehavioral features that reflect
FRDA patients113-115. The Knock-in/Wild type mouse (KIWT) serves as control; this mouse has
one wild type FXN allele and a humanized expansion sequence in the second FXN allele. While
still limited by the inherent differences between mice and humans, these models provide valuable
data that supplement in vitro results.
The goal of this chapter is to investigate the effects of SS-31 in both in vivo and in vitro
models of FRDA. First, the effects of SS-31 on FXN levels in the KIWT and KIKO cerebellum are
investigated. Then, the effects of SS-31 on protein levels, mitochondrial fragmentation, (Ser616)
phospho-Drp1 clustering, and ATP levels are investigated in the sub-acute and chronic fibroblast
in vitro FRDA models. These data provide information regarding the therapeutic potential for SS31 in FRDA and provides further insight into the mechanism of action of SS-31.

4.3 Murine model with SS-31
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To determine the in vivo effects of SS-31 on protein levels, KIWT and KIKO mice were
subcutaneously injected with SS-31 at 5mg/kg bodyweight. KIWT mice injected with SS-31
exhibit significantly increased levels of FXN in the cerebellum by 256% (Fig. 4.2.1); contrarily, the
levels of FXN were unaltered in the cerebella of KIKO mice were unaltered by SS-31 treatment
(Fig.4.2.2) In KIWT cerebellum, this drug significantly increased the levels of Drp1 and (Ser616)
phospho-Drp1 by 148% and 149% respectively, although the ratio between the phosphorylated
form and total level of Drp1 remained unchanged (Fig. 4.2.2). In KIKO cerebellum, the levels of
Drp1 and (Ser616) phospho-Drp1 were unchanged, although SS-31 resulted in a non-significant
trend toward increasing the ratio of (Ser616) phospho-Drp1 to total Drp1 levels (Fig. 4.2.4)

Fig. 4.3.1 SS-31 increases the level of FXN in KIWT cerebellum. Representative Western blot of
cerebellum from KIWT mice treated with SS-31 or vehicle control (A). SS-31 increased FXN
levels to 256% the levels in vehicle-treated KIWT mice treated (B). **p<0.01, two-sided t-test.
n=3.

58

Fig. 4.3.2 SS-31 does not alter the level of FXN in KIKO cerebellum. Representative Western
blot of cerebellum from KIKO mice treated with SS-31 or vehicle control (A). SS-31 did not
significantly alter the level of FXN in KIKO cerebellum (B). n. s. not significant, two-sided t-test.
n=3.
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Fig. 4.3.3 SS-31 increases the levels of Drp1 and (Ser616) phospho-Drp1 in KIWT cerebellum
but does not alter the ratio between these two levels. Representative Western blot of cerebellum
from KIWT mice treated with SS-31 or vehicle control (A). SS-31 increased the level of (Ser616)
phospho-Drp1 by 148% (B) and increased the level of Drp1 by 149% (C). The ratio between the
level of (Ser616) phospho-Drp1 and Drp1 was unaffected by SS-31 (D). n. s. not significant,
**p<0.01, two-sided t-test. n=3.
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Fig. 4.3.4 SS-31 does not alter the levels of or ratio between Drp1 and (Ser616) phospho-Drp1 in
KIKO cerebellum. Representative Western blot of cerebellum from KIKO mice treated with SS-31
or vehicle control (A). SS-31 did not significantly alter the levels of (Ser616) phospho-Drp1 (A),
Drp1 (B), or the ratio between the levels of (Ser616) phospho-Drp1 and Drp1 (C). n. s. not
significant, two-sided t-test. n=3

4.4 Patient-derived cells with SS-31
To determine the effects of SS-31 on a model of chronic FXN deficiency, 2 FRDA patientderived fibroblast cell lines were treated with 1 µM SS-31 for 72 hours. SS-31 treatment
significantly decreased the level of FXN in FRDA patient-derived fibroblasts to 42% of the levels
in vehicle-treated controls (Fig. 4.3.1), although it did not affect the overall levels of (Ser616)
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phospho-Drp1 or Drp1 (Fig. 4.3.2). This drug significantly decreased the number of mitochondrial
fragments per cell (419 to 150 fragments per cell, Fig. 4.3.3) as well as the number of (Ser616)
phospho-Drp1 clusters per cell (892 to 479 clusters per cell, Fig. 4.3.4). The ATP levels in FRDA
patient-derived fibroblasts were unaltered by SS-31 treatment (Fig. 4.3.5).

Fig. 4.4.1 SS-31 significantly decreased the level of FXN in FRDA patient-derived fibroblasts.
Representative Western blot of FRDA patient-derived fibroblasts treated with SS-31 (A). This
drug significantly decreased FXN levels to 42% of control levels (B). *p>0.05, Wilcoxon sum-rank
test. n=2 technical replicates for each of 5 biological replicates.
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Fig. 4.4.2 SS-31 does not alter the levels of Drp1 or (Ser616) phospho-Drp1 in FRDA patientderived fibroblasts. Representative Western blot of FRDA patient-derived fibroblasts treated with
SS-31 (A). This drug did not significantly alter the levels of (Ser616) phospho-Drp1 or Drp1 (B).
n=2 technical replicates for each of 5 biological replicates.

Fig. 4.4.3 SS-31 significantly decreases the number of mitochondrial fragments per cell in FRDA
patient-derived fibroblasts. ICC for a mitochondrial marker in FRDA patient-derived fibroblasts
treated with a vehicle control (A) or with SS-31 (B). This drug decreased the number of
mitochondrial fragments per cell from 419 to 150 (C). ***p<0.001, two-sided t-test. n=4 technical
replicates for each of 2 biological replicates.
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Fig. 4.4.4 SS-31 significantly decreases the number of (Ser616) phospho-Drp1 clusters per cell in
FRDA patient-derived fibroblasts. ICC for (Ser616) phospho-Drp1 in FRDA patient-derived
fibroblasts treated with a vehicle control (A) or SS-31 (B). SS-31 decreased the number of
(Ser616) phospho-Drp1 clusters per cell from 892 to 479 (C). *p<0.05, two-sided t-test. n=4
technical replicates for each of 2 biological replicates.
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Fig. 4.4.5 SS-31 does not alter the level of ATP in FRDA patient-derived fibroblasts.
Luminescence-based assay for quantifying the relative amount of ATP in cells revealed that SS31 does not significantly alter ATP levels (A). n. s. not significant, two-sided t-test. n=2 technical
replicates for each of 5 biological replicates.

4.5 Combination of TAT-P110 and SS-31 in patient-derived cells
To determine whether TAT-P100 and SS-31 act on the same pathway, 3 FRDA patientderived fibroblast cell lines were treated with a combination of 1 µM TAT-P110 and 1 µM SS-31
for 72 hours. This drug combination did not alter the levels of FXN, Drp1, of (Ser616) phosphoDrp1 differently from SS-31 alone (Fig. 4.4.1 and Fig. 4.4.2). Similarly, the number of
mitochondrial fragments and the number of (Ser616) phospho-Drp1 clusters were unchanged
when comparing the combination treatment to treatment with SS-31 alone (Fig. 4.4.3 and Fig.
4.4.4). The ATP levels in FRDA patient-derived cells treated with the drug combination trended
toward a decrease compared to treatment with SS-31 alone (Fig. 4.4.5).
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Fig. 4.5.1 The combination of TAT-P110 and SS-31 does not alter the level of FXN in FRDA
patient-derived fibroblasts compared with SS-31 alone. Representative Western blot of FRDA
patient-derived fibroblasts treated with a combination of TAT-P110 and SS-31 (A). The drug
combination did not alter FXN levels differently from treatment with SS-31 alone (B). n. s. not
significant, Wilcoxon sum-rank test. n=5 biological replicates.

Fig. 4.5.2 The combination of TAT-P110 and SS-31 does not alter the overall levels of Drp1 or
(Ser616) phospho-Drp1 in FRDA patient-derived fibroblasts compared with SS-31 alone.
Representative Western blot of FRDA patient-derived fibroblasts treated with a combination of
TAT-P110 and SS-31 (A). The drug combination did not alter (Ser616) phospho-Drp1 or Drp1
levels differently from treatment with SS-31 alone (B). n. s. not significant, Wilcoxon sum-rank
test. n=5 biological replicates.
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Fig. 4.5.3 The combination of TAT-P110 and SS-31 does not alter the number of mitochondrial
fragments per FRDA patient-derived fibroblast compared to SS-31 alone. ICC for a mitochondrial
marker in FRDA patient-derived fibroblasts treated with SS-31 alone (A) or with a combination of
TAT-P110 and SS-31 (B). The drug combination did not significantly change the number of
mitochondrial fragments per cell compared to treatment with SS-31 alone (B). n. s. not
significant, two-sided t-test. n=3 technical replicates for each of 3 biological replicates.
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Fig. 4.5.4 The combination of TAT-P110 and SS-31 does not alter the number of (Ser616)
phospho-Drp1 clusters per FRDA patient-derived fibroblast compared with SS-31 alone. ICC for
(Ser616) phospho-Drp1 in FRDA patient-derived fibroblasts treated with SS-31 alone (A) or with a
combination of TAT-P110 and SS-31 (B). The drug combination did not significantly change the
number of (Ser616) phospho-Drp1 clusters per cell compared to treatment with SS-31 alone (B).
n. s. not significant, two-sided t-test. n=3 technical replicates for each of 3 biological replicates.
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Fig. 4.5.5 The combination of TAT-P110 and SS-31 trends toward decreasing the number of
(Ser616) phospho-Drp1 clusters per FRDA patient-derived fibroblast compared with SS-31 alone.
Luminescence-based assay reveals that a combination of TAT-P110 and SS-31 did not alter ATP
levels compared to treatment with SS-31 alone (A). n. s. not significant, two-sided t-test. n=2
technical replicates for each of 5 biological replicates.

4.6 Discussion
The pathophysiological hallmarks of FRDA, including dysmetria and dysarthria, likely
stem from abnormalities in the cerebellum, particularly the dentate nucleus 136,137; improving
cerebellar functioning would thus likely prove beneficial for FRDA patients. While SS-31
increased FXN levels in KIWT cerebellum, FXN was unaffected in KIKO cerebellum. Perhaps
SS-31 slows the rate of FXN turnover in KIWT but is incapable of achieving this effect in KIKO.
Another possibility includes SS-31 indirectly affecting FXN transcription; since FXN may be
silenced through methylation in FRDA patients30, the effects of SS-31 on protein levels may differ
in KIWT and KIKO because of their different methylation patterns. Further investigation is
necessary to explore those potential hypotheses.
This expression pattern (i.e. increasing FXN in control models while leaving FXN levels
unaffected in FRDA models) is typical of other pre-clinical drug trials in FRDA models
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(unpublished data). These results therefore suggest that a multi-drug approach to FRDA may
prove a more effective therapeutic strategy than utilizing a single-target drug.
SS-31 decreases the level of FXN in FRDA patient-derived fibroblasts, but another group
reports that SS-31 increases FXN levels in FRDA patient lymphoblasts 87. This group treated the
lymphoblasts for a 24-hour time course; it is possible that SS-31 results in a transient increase in
FXN levels that reverses by 72 hours of treatment. Additionally, the differences in these results
may reflect tissue-specific effects of SS-31. Finally, this group utilized a cell line from one FRDA
patient while the experiments shown here utilize cell lines derived from 2-5 FRDA patients.
Variability exists between individuals (e.g. age, sex), and this variability is further compounded in
FRDA (e.g. GAA repeat length, age of disease onset). The difference between these results may
reflect differential responses between individual patients. Utilizing cell lines from multiple FRDA
patients and correlating the results with disease factors, particularly GAA repeat length, is critical
for data interpretation. The mitochondrial fragmentation and (Ser616) phospho-Drp1 cluster
analyses presented in this dissertation use 2-3 biological replicates; while the results demonstrate
that these features affect multiple individuals, the limited number of biological replicates has
insufficient power to provide correlative data between GAA repeat length and the number of
mitochondrial fragments and/or (Ser616) phospho-Drp1 clusters. Future experiments seeking to
draw such correlative conclusions should utilize an increased number of biological replicates.
In FRDA patient-derived fibroblasts, SS-31 significantly decreases the number of
mitochondrial fragments per cell as well as the number of (Ser616) phospho-Drp1 clusters per
cell. This effect may in part be attributed to SS-31 stabilizing CL, since this phospholipid plays a
critical role in maintaining the mitochondrial structure81. Additionally, the action of SS-31 may
potentiate CL’s roles in anchoring the ETC to the IMM and in bringing the ETC complexes within
close proximity to one another, thereby improving cellular respiration 82,83. This improvement to
bioenergetics may activate mitochondrial fusion, as fragmentation may no longer be necessary to
maintain ATP homeostasis in FRDA patient cells treated with SS-31. Despite reversing
fragmentation, ATP levels are maintained during SS-31 treatment; contrast this to TAT-P110
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treatment in which fragmentation is reversed, but ATP levels are decreased. While SS-31 and
TAT-P110 may both act on a pathway that contributes to mitochondrial fragmentation, the
difference in these ATP level results suggests that these drugs have different targets. Any loss in
ATP synthesis from reversing fragmentation in SS-31-treated cells may be counteracted by
increased ATP synthesis resulting from improvements to ETC function. Therefore, if a potential
therapeutic approach to FRDA reverses fragmentation, it must simultaneously improve another
aspect of bioenergetics in order to be viable.
To further define the ability of SS-31 to ameliorate metabolic deficiencies in FRDA
through protecting lipids against oxidative damage, a future experiment may include the use of
BODIPY 581/591 C11 (Invitrogen D3861). This fluorescent dye detects ROS in cell culture; upon
oxidation of the polyunsaturated butadienyl portion of the dye, the fluorescence emission peak
shifts in wavelength. BODIPY 581/591 C11 may then detect whether SS-31 decreases ROS
accumulation, thereby decreasing oxidative damage, in primary FRDA cell culture.
Since an optimal therapeutic strategy for FRDA will likely involve targeting multiple
pathways, analyzing the direct targets of drugs and the pathways they affect is critical for rational
drug design. The combination of TAT-P110 and SS-31 does not affect FRDA patient-derived
fibroblasts differently from SS-31 alone. The trending decrease in ATP levels mirrors the effect of
treating FRDA patient-derived fibroblasts TAT-P110 individually and can therefore be attributed to
this drug. The lack of differences between the drug combination and SS-31 alone suggests that
these drugs act on the same pathway; if they act on different pathways, the two drugs would likely
work synergistically, resulting in increased effects compared to either drug individually. As such,
this drug combination would likely be relatively ineffective in vivo. A combination of SS-31, which
improves bioenergetics in FRDA patient-derived cells, and a drug that acts on another pathway
(e.g. an Nrf2 activator, see Chapter 5), would likely prove to be a more optimal therapeutic
strategy.
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CHAPTER 5- CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Conclusions regarding TAT-P110 and SS-31 in Friedreich ataxia

TAT-P110 and SS-31 both effectively inhibit mitochondrial fragmentation through
decreasing Drp1 activity in sub-acute and chronic models of FRDA. Both drugs result in
decreased (Ser616) phospho-Drp1 clustering at the mitochondria; while TAT-P110 directly
inhibits this Drp1 activity, it is a downstream effect of SS-31’s mechanism of action. Treating cells
with a combination of these two drugs does not result in different effects than treating with one
drug, suggesting that the drugs affect the same enzymatic pathway. However, they target
different points along that pathway. This becomes apparent when observing the effects of these
drugs on ATP levels. See Figure 5.1.1 for the putative pathway by which FXN deficiency causes
mitochondrial fragmentation and the points at which TAT-P110 and SS-31 exert their effects.
TAT-P110 selectively inhibits Drp1 activity, resulting in significantly decreased ATP levels
in FXN-knockdown cells and a trend toward decreasing ATP in FRDA patient fibroblasts.
Contrarily, SS-31 does not alter the ATP levels in FRDA patient fibroblasts, suggesting that SS31 acts upstream of Drp1 activity. Indeed, SS-31 acts upon CL to improve ETC function and
potentially to protect this phospholipid from oxidation. Therefore, as FXN deficiency in FRDA
impairs ETC functioning through decreased ISC biosynthesis, ETC dysfunction occurs prior to
mitochondrial fragmentation in FRDA.
While FXN transfection reverses mitochondrial fragmentation in FRDA patient fibroblasts,
it does not increase ATP levels by the 72-hour time point. It is possible that under chronic FXN
deficiency, cells preferentially use the oxidative-phosphorylation pathway to generate ATP rather
than glycolysis. As the cells have switched ATP-synthesizing pathways, FXN re-expression may
take longer than 72 hours to increase ATP levels as the cells switch back to utilizing glycolysis. It
is possible that other features of FRDA, like iron toxicity may also contribute to mitochondrial

72

fragmentation. Perhaps FXN re-expression is capable of restoring such toxicity within the 72hour time point, resulting in fused mitochondria without restoring ATP levels. Therefore, multiple
pathologies, including ETC dysfunction, appear to present temporally before mitochondrial
fragmentation in FRDA.

Fig. 5.1.1 Potential pathway resulting in excessive mitochondrial fragmentation in FRDA. FXN
deficiency impairs ISC biosynthesis, which in turn impairs ETC function, decreasing ATP levels.
In response, Drp1 is phosphorylated at (Ser616), is recruited to the mitochondria by Mcl1, and
executes mitochondrial fragmentation. At least sub-acutely, fragmentation is homeostatic
mechanism that allows the cells to maintain ATP levels, although this mechanism fails as the
cells enter a chronic state of FXN deficiency. TAT-P110 inhibits Drp1 activity, thus preventing
mitochondrial fragmentation and, in the sub-acute model, decreasing ATP levels. SS-31
improves ETC functioning, decreasing Drp1 activation, and reversing mitochondrial
fragmentation. While the improved ETC functioning would increase ATP levels, this effect may
be counteracted by the loss of fragmentation as a homeostatic mechanism. Through
mechanisms not fully elucidated, ETC dysfunction may cause the cell to upregulate FXN
expression, since improved ETC functioning results in decreased FXN levels (at the 72-hour
timepoint in FRDA patient fibroblasts). SS-31 and TAT-P110 thus operate at different points
along the same pathway.
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5.2 Preliminary results to guide future work on Nrf2 activators

One small molecule Nrf2 activator is RTA-408 (omaveloxelone). This drug inhibits the
interaction between Nrf2 and Keap1, improving bioenergetics in both in vitro and rodent models
of FRDA138; furthermore, in phase I and phase II clinical trials, FRDA patients on RTA-408
experienced a significant reversal in disease progression100. To better understand the
mechanism of action of this drug in FRDA, the effects of RTA-408 on mitochondrial dynamics,
ATP levels, and FXN levels were studied.
To determine the effects of RTA-408 on mitochondrial fragmentation, healthy fibroblasts
with FXN knockdown were treated with 100nM RTA-408 for 72 hours. This drug significantly
decreased the number of mitochondrial fragments per cell (Fig. 5.2.1) as well as the number of
(Ser616) phospho-Drp1 clusters per cell (Fig. 5.2.2). When applied to FRDA patient-derived
fibroblasts, however, 100nM RTA-408 did not significantly alter the number of mitochondrial
fragments (Fig. 5.2.3) or the number of (Ser616) phospho-Drp1 clusters (Fig. 5.2.4) per cell. To
further explore the pathway on which Nrf2 activators may exert their effects in FRDA patients, an
RNA seq dataset was interrogated. While FRDA patient fibroblasts have significantly decreased
Nrf2 transcript levels, KEAP1 transcript levels are unchanged; however, Hrd1 transcript levels are
significantly increased (Fig. 5.2.5).
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Fig. 5.2.1 RTA-408 decreases the number of mitochondrial fragments in FXN-knockdown
fibroblasts. ICC for a mitochondrial marker in FXN-knockdown fibroblasts treated with vehicle (A)
or 100nM RTA-408 (B). This drug significantly decreased the number of mitochondrial fragments
per cell from 1233 to 645 (C). **p<0.01, two-sided t-test. n=3.
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Fig. 5.2.2 RTA-408 decreases the number of (Ser616) phospho-Drp1 clusters per cell in FXNknockdown fibroblasts. ICC for (Ser616) phospho-Drp1 in FXN-knockdown fibroblasts treated
with vehicle (A) or 100nM RTA-408 (B). This drug significantly decreased the number of (Ser616)
phospho-Drp1 clusters per cell from 444 to 293 (C). *p<0.05, two-sided t-test. n=3.
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Fig. 5.2.3 RTA-408 does not change the number of mitochondrial fragments per cell in FRDA
patient fibroblasts. ICC for a mitochondrial marker in FRDA patient-derived fibroblasts treated
with vehicle (A) or 100nM RTA-408 (B). This drug did not significantly alter the number of
mitochondrial fragments per cell (C). n. s. not significant, two-tailed t-test. n=3 technical
replicates for each of 3 biological replicates.
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Fig. 5.2.4 RTA-408 does not change the number of (Ser616) phospho-Drp1 clusters per cell in
FRDA patient fibroblasts. ICC for (Ser616) phospho-Drp1 in FRDA patient-derived fibroblasts
treated with vehicle (A) or 100nM RTA-408 (B). This drug did not significantly alter the number of
(Ser616) phospho-Drp1 clusters per cell (C). n. s. not significant, two-tailed t-test. n=3 biological
replicates for each of 3 technical replicates.
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Fig. 5.2.5 Nrf2 pathway gene transcript levels are altered in FRDA patient fibroblasts. These data
are derived from the normalized levels of mRNA transcripts. FRDA patient cells exhibit
significantly decreased Nrf2 transcripts (90% of healthy controls, A). KEAP1 transcript levels
were not significantly altered (B). Hrd1 transcript levels are significantly increased to 130% the
levels observed in healthy controls (C). n. s. not significant, *p<0.05, **p<0.01, two-sided t-test.
n=17.
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5.3 Conclusions regarding therapeutic approaches to Friedreich ataxia

FRDA cells exhibit excessive mitochondrial fragmentation that begins rapidly following
FXN deficiency. This mitochondrial fragmentation is a direct result of FXN deficiency and
restoring FXN levels reverses fragmentation. Additionally, fragmentation in FRDA is dependent
upon Drp1 activity; FRDA cells exhibit increased clustering of (Ser616) phospho-Drp1 at the
mitochondria. This excessive Drp1-dependent mitochondrial fragmentation may be used as a
biomarker disease, although it is not specific to FRDA. Moreover, although excessive
fragmentation is a feature of FRDA, it is not necessarily pathogenic; contrarily the data suggest
that mitochondrial fragmentation is an adaptive mechanism in FRDA. Inhibiting fragmentation
decreases ATP level in the sub-acute model and trends toward decreasing ATP in the chronic
model. Therefore, while the amount of fragmentation may be utilized as a biomarker, reversing
fragmentation should not serve as the sole rationale behind drug development for FRDA.
Rather, mitochondrial fragmentation may be used as one endpoint measure for drug
effectiveness: a drug may exert its effect on a different target (e.g. the ETC), and as a
consequence of the improved bioenergetics, the cell may reverse mitochondrial fragmentation.
This appears to be the case with SS-31; this drug improves ETC function, and as a result, the cell
may inhibit mitochondrial fragmentation (as well as potentially activating mitochondrial fusion). In
contrast, a drug like TAT-P110 that directly targets and inhibits mitochondrial fragmentation does
not appear to be a viable therapeutic approach. Directly inhibiting a homeostatic mechanism
without improving some other cellular function is not a rational approach to drug design. TATP110 may be effective at improving bioenergetics for diseases in which fragmentation is a
maladaptive mechanism; however, as fragmentation is homeostatic in FRDA, TAT-P110 alone
would likely prove ineffective at improving bioenergetics.
While reversing fragmentation may not confer bioenergetics benefits to the cell, it may
benefit the cell through other pathways. The mitochondrial network interconnects with numerous
other protein networks that are critical for protein synthesis and translocation139. Excessive
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mitochondrial fragmentation increases cellular susceptibility to apoptotic stimuli 140. Additionally,
the fused mitochondrial network efficiently transports mitochondrial DNA (mtDNA) and is critical
for mtDNA repair141. Because accumulation of damaged mtDNA is a pathogenic feature of
numerous diseases142, maintenance of a fused mitochondrial network may benefit the cell.
Therefore, it is possible that reversing mitochondrial fragmentation in FRDA may be beneficial if a
pharmacologic agent can simultaneously protect against the resultant decrease in ATP levels.
In addition to improving bioenergetics, increasing the levels of antioxidant response
elements may be a viable therapeutic approach. Nrf2 activators, such as RTA-408 and
potentially LS-102, may represent viable drugs to improve the cell’s response to oxidant stress in
FRDA100,103. Even if oxidative damage is reduced, however, bioenergetics are likely to still be
impaired. Therefore, targeting both the antioxidant response element pathway (e.g. Nrf2
activation) and a bioenergetics pathway (e.g. ETC stabilization) may present a more optimal
therapeutic strategy than targeting any one pathway individually.
However, FRDA is a multi-tissue disease, and as such, it is very possible that different
therapeutic strategies will be required for different tissues. It will therefore be critical to
investigate the effects of drugs in several tissue types and perhaps to increase drug delivery
precision to specific cell types.
While highly optimized therapeutic strategies for FRDA are years away, the findings
presented in this dissertation provide valuable information in developing such therapies. This
thesis provides novel insights into the role of mitochondrial dynamics in FRDA, begins to detail
the mechanisms of action for two potentially therapeutic peptides in FRDA models, and suggests
how more optimized therapeutic approaches may be designed.

81

APPENDIX

# Joseph Johnson
# October 19, 2020
# Doctoral Dissertation in Pharmacology at the University of Pennsylvan
ia
# Appendix 1
# This code queries the GSE104288 database first published by Napierala
et al 2017, PMID: 32291635.
# The dataset contains normalized RNA transcript levels from fibroblast
s derived from
# 17 healthy controls and 18 FRDA patients.
# Load the necessary packages
library(tidyverse)
## -- Attaching packages --------------------------------------- tidyve
rse 1.3.0 -##
##
##
##

v
v
v
v

ggplot2
tibble
tidyr
readr

3.3.0
3.0.0
1.0.2
1.3.1

v
v
v
v

purrr
dplyr
stringr
forcats

0.3.4
0.8.5
1.4.0
0.5.0

## -- Conflicts ------------------------------------------ tidyverse_co
nflicts() -## x dplyr::filter() masks stats::filter()
## x dplyr::lag()
masks stats::lag()
## x dplyr::recode() masks car::recode()
## x purrr::some()
masks car::some()
library(GEOquery)
## Loading required package: Biobase
## Loading required package: BiocGenerics
## Loading required package: parallel
##
## Attaching package: 'BiocGenerics'
## The following objects are masked from 'package:parallel':
##
##
clusterApply, clusterApplyLB, clusterCall, clusterEvalQ,
##
clusterExport, clusterMap, parApply, parCapply, parLapply,
##
parLapplyLB, parRapply, parSapply, parSapplyLB
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## The following objects are masked from 'package:dplyr':
##
##
combine, intersect, setdiff, union
## The following objects are masked from 'package:stats':
##
##
IQR, mad, sd, var, xtabs
## The
##
##
##
ep,
##
##
##
##

following objects are masked from 'package:base':
anyDuplicated, append, as.data.frame, basename, cbind, colnames,
dirname, do.call, duplicated, eval, evalq, Filter, Find, get, gr
grepl,
order,
rbind,
union,

intersect, is.unsorted, lapply, Map, mapply, match, mget,
paste, pmax, pmax.int, pmin, pmin.int, Position, rank,
Reduce, rownames, sapply, setdiff, sort, table, tapply,
unique, unsplit, which, which.max, which.min

## Welcome to Bioconductor
##
##
Vignettes contain introductory material; view with
##
'browseVignettes()'. To cite Bioconductor, see
##
'citation("Biobase")', and for packages 'citation("pkgname")'.
## Setting options('download.file.method.GEOquery'='auto')
## Setting options('GEOquery.inmemory.gpl'=FALSE)
library(GEOmetadb)
## Loading required package: RSQLite
library(BiocFileCache)
## Loading required package: dbplyr
##
## Attaching package: 'dbplyr'
## The following objects are masked from 'package:dplyr':
##
##
ident, sql
# Display the metadata
gse104288 <- getGEO("GSE104288", GSEMatrix = TRUE)
## Found 1 file(s)
## GSE104288_series_matrix.txt.gz
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## Parsed with column specification:
## cols(
##
.default = col_character()
## )
## See spec(...) for full column specifications.
## File stored at:
## C:\Users\johns\AppData\Local\Temp\RtmpYhyHBV/GPL11154.soft
show(gse104288)
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##

$GSE104288_series_matrix.txt.gz
ExpressionSet (storageMode: lockedEnvironment)
assayData: 0 features, 35 samples
element names: exprs
protocolData: none
phenoData
sampleNames: GSM2794401 GSM2794402 ... GSM2794435 (35 total)
varLabels: title geo_accession ... tissue:ch1 (44 total)
varMetadata: labelDescription
featureData: none
experimentData: use 'experimentData(object)'
pubMedIds: 29125828
31665133
32291635
Annotation: GPL11154

show(pData(phenoData(gse104288[[1]]))[1:35,c(1,10,12)])
##
2
##
y
##
y
##
y
##
y
##
d
##
y
##
y
##
y

title

characteristics_ch1 characteristics_ch1.

GSM2794401

C1650

genotype: Control

sampling age: 37

GSM2794402

C2036

genotype: Control

sampling age: 11

GSM2794403

C2153

genotype: Control

sampling age: 40

GSM2794404

C2169

genotype: Control

sampling age: 52

GSM2794405 C21808

genotype: Control

sampling age: 1

GSM2794406

C2671

genotype: Control

sampling age: 47

GSM2794407

C288

genotype: Control

sampling age: 64

GSM2794408

C3348

genotype: Control

sampling age: 10
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##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y
##
y

GSM2794409

C3652

genotype: Control

sampling age: 24

GSM2794410

C3956

genotype: Control

sampling age: 27

GSM2794411

C5879

genotype: Control

sampling age: 48

GSM2794412

C7492

genotype: Control

sampling age: 17

GSM2794413

C7522

genotype: Control

sampling age: 19

GSM2794414

C7525

genotype: Control

sampling age: 22

GSM2794415

C8399

genotype: Control

sampling age: 19

GSM2794416

C_UF

genotype: Control

sampling age: 35

GSM2794417

C_UM

genotype: Control

sampling age: 39

GSM2794418

F130 genotype: Friedreich's ataxia

sampling age: 56

GSM2794419

F156 genotype: Friedreich's ataxia

sampling age: 41

GSM2794420

F188 genotype: Friedreich's ataxia

sampling age: 47

GSM2794421

F203 genotype: Friedreich's ataxia

sampling age: 31

GSM2794422

F281 genotype: Friedreich's ataxia

sampling age: 19

GSM2794423

F3665 genotype: Friedreich's ataxia

sampling age: 13

GSM2794424

F4078 genotype: Friedreich's ataxia

sampling age: 30

GSM2794425

F4192 genotype: Friedreich's ataxia

sampling age: 33

GSM2794426

F4230 genotype: Friedreich's ataxia

sampling age: 28

GSM2794427

F4259 genotype: Friedreich's ataxia

sampling age: 37

GSM2794428

F4497 genotype: Friedreich's ataxia

sampling age: 44

GSM2794429

F4509 genotype: Friedreich's ataxia

sampling age: 36

GSM2794430

F4627 genotype: Friedreich's ataxia

sampling age: 50

GSM2794431

F4654 genotype: Friedreich's ataxia

sampling age: 19

GSM2794432

F4675 genotype: Friedreich's ataxia

sampling age: 28
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## GSM2794433
y
## GSM2794434
y
## GSM2794435
y

F66 genotype: Friedreich's ataxia

sampling age: 70

F68 genotype: Friedreich's ataxia

sampling age: 21

F88 genotype: Friedreich's ataxia

sampling age: 50

# Read the dataset and title it "GE"
GeneExpressionTable <- read.table("GSE104288_DESeq_counts.txt", header
= TRUE, sep = "\t")
GE <- as_tibble(GeneExpressionTable)
# To validate that this code functions properly, the levels of FXN and
ISCU transcripts were investigated
# since it is well established that these proteins are downregulated in
FRDA patients.
# Indeed, both FXN and ISCU transcripts are significantly decresed in F
RDA patients
# when running this code on the GSE104288 database.
# FXN Levels
FXNLevels <- filter(GE, gene=="FXN")
ControlGroupFXN <- select(FXNLevels, starts_with("C"))
FAGroupFXN <- select(FXNLevels, starts_with("F"))
t.test(ControlGroupFXN, FAGroupFXN, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupFXN and FAGroupFXN
t = 10.532, df = 32.666, p-value = 4.915e-12
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
61.54421 91.02898
sample estimates:
mean of x mean of y
135.53147 59.24487

sd(ControlGroupFXN)/sqrt(length(ControlGroupFXN))
## [1] 5.299988
sd(FAGroupFXN)/sqrt(length(FAGroupFXN))
## [1] 4.937195
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#ISCU Levels
ISCULevels <- filter(GE, gene=="ISCU")
ControlGroupISCU <- select(ISCULevels, starts_with("C"))
FAGroupISCU <- select(ISCULevels, starts_with("F"))
t.test(ControlGroupISCU, FAGroupISCU, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupISCU and FAGroupISCU
t = 2.4885, df = 25.716, p-value = 0.01964
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
84.40447 888.31498
sample estimates:
mean of x mean of y
2402.204 1915.844

# As RTA-408 (omaveloxolone) inhibits KEAP1 from ubiquitinating Nrf2,
# the levels of KEAP1 and Nrf2 transcripts were examined.
# KEAP1 Levels
KEAP1Levels <- filter(GE, gene=="KEAP1")
ControlGroupKEAP1 <- select(KEAP1Levels, starts_with("C"))
FAGroupKEAP1 <- select(KEAP1Levels, starts_with("F"))
t.test(ControlGroupKEAP1, FAGroupKEAP1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupKEAP1 and FAGroupKEAP1
t = 0.97753, df = 32.179, p-value = 0.3356
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-43.41189 123.55907
sample estimates:
mean of x mean of y
1647.714 1607.640

sd(ControlGroupKEAP1)/sqrt(length(ControlGroupKEAP1))
## [1] 30.80597
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sd(FAGroupKEAP1)/sqrt(length(FAGroupKEAP1))
## [1] 27.04746
# Nrf2 Levels (endoded by NFE2L2)
Nrf2Levels <- filter(GE, gene=="NFE2L2")
ControlGroupNrf2 <- select(Nrf2Levels, starts_with("C"))
FAGroupNrf2 <- select(Nrf2Levels, starts_with("F"))
t.test(ControlGroupNrf2, FAGroupNrf2, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupNrf2 and FAGroupNrf2
t = 2.0398, df = 32.509, p-value = 0.04957
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
0.4062241 405.4493682
sample estimates:
mean of x mean of y
2117.697 1914.769

sd(ControlGroupNrf2)/sqrt(length(ControlGroupNrf2))
## [1] 64.73632
sd(FAGroupNrf2)/sqrt(length(FAGroupNrf2))
## [1] 75.54224
# Although Nrf2 transcript levels are decreased, KEAP1 transcript level
s are unaffected.
# It is therefore possible that Nrf2 is further regulated by another E3
ubiquitin ligase in FRDA.
# To examine this, Hrd1 trancript levels were investigated.

# Hrd1 Levels (encoded by SYVN1)
SYVN1Levels <- filter(GE, gene=="SYVN1")
ControlGroupSYVN1 <- select(SYVN1Levels, starts_with("C"))
FAGroupSYVN1 <- select(SYVN1Levels, starts_with("F"))
t.test(ControlGroupSYVN1, FAGroupSYVN1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
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##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupSYVN1 and FAGroupSYVN1
t = -3.309, df = 32.757, p-value = 0.002283
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-162.83909 -38.81807
sample estimates:
mean of x mean of y
336.6194 437.4480

# Indeed, Hrd1 levels are significantly
# It is therefore conceivable that Hrd1
nregulation
# in FRDA patients than KEAP1.
# This suggests that an Hrd1 inhibitor,
cial for FRDA patients
# than a KEAP1 inhibitor/Nrf2 acitvator

increased in FRDA patients.
plays a larger role in Nrf2 dow
like LS-102, may be more benefi
like RTA-408

# Transcript levels of Drp1 are unchanged in FRDA patients.
# This further validates that Drp1 protein levels are unchanged in FRDA
patient fibroblasts;
# rather, FRDA patients exhibit increased Drp1 clustering at the mitoch
ondria.
#Drp1 Levels (encoded by gene DNM1L)
DNM1LLevels <- filter(GE, gene=="DNM1L")
ControlGroupDNM1L <- select(DNM1LLevels, starts_with("C"))
FAGroupDNM1L <- select(DNM1LLevels, starts_with("F"))
t.test(ControlGroupDNM1L, FAGroupDNM1L, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupDNM1L and FAGroupDNM1L
t = -0.75214, df = 29.524, p-value = 0.4579
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-269.0664 124.2946
sample estimates:
mean of x mean of y
1920.307 1992.693
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sd(ControlGroupDNM1L)/sqrt(length(ControlGroupDNM1L))
## [1] 77.9672
sd(FAGroupDNM1L)/sqrt(length(FAGroupDNM1L))
## [1] 56.41979
# CDK1 phosphorylates Drp1 at Ser616, activating the latter protein's G
TPase activity.
# CDK1 transcript levels are significantly increased.
#CDK1 Levels
CDK1Levels <- filter(GE, gene=="CDK1")
ControlGroupCDK1 <- select(CDK1Levels, starts_with("C"))
FAGroupCDK1 <- select(CDK1Levels, starts_with("F"))
t.test(ControlGroupCDK1, FAGroupCDK1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupCDK1 and FAGroupCDK1
t = -2.9291, df = 17.816, p-value = 0.009033
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-1332.9735 -218.9957
sample estimates:
mean of x mean of y
293.4558 1069.4404

sd(ControlGroupCDK1)/sqrt(length(ControlGroupCDK1))
## [1] 40.59105
sd(FAGroupCDK1)/sqrt(length(FAGroupCDK1))
## [1] 261.7923
# Mcl1 chpaerones Drp1 to the mitochondria.
# Atlhough Mcl1 protiens levels are increased in FXN knockdown fibrobla
sts,
# Mcl1 transcript levels are unaffected in FRDA patients.
# This may reflect an inherent difference between sub-acute and chronic
FRDA models
# or Mcl1 protein levels may be regulated post-transcription.
# MCL1 Levels
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Mcl1Levels <- filter(GE, gene=="MCL1")
ControlGroupMcl1 <- select(Mcl1Levels, starts_with("C"))
FAGroupMcl1 <- select(Mcl1Levels, starts_with("F"))
t.test(ControlGroupMcl1, FAGroupMcl1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupMcl1 and FAGroupMcl1
t = -0.51358, df = 24.953, p-value = 0.6121
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-1337.5235
803.6366
sample estimates:
mean of x mean of y
6834.972 7101.915

sd(ControlGroupMcl1)/sqrt(length(ControlGroupMcl1))
## [1] 233.0554
sd(FAGroupMcl1)/sqrt(length(FAGroupMcl1))
## [1] 464.5882
# OPA1 regulates fusion of the inner mitochondrial membrane.
# OPA1 transcript levels trend toward decresasing in FRDA patients.
#OPA1 Levels
OPA1Levels <- filter(GE, gene=="OPA1")
ControlGroupOPA1 <- select(OPA1Levels, starts_with("C"))
FAGroupOPA1 <- select(OPA1Levels, starts_with("F"))
t.test(ControlGroupOPA1, FAGroupOPA1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupOPA1 and FAGroupOPA1
t = -1.94, df = 29.599, p-value = 0.06197
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-309.473225
8.038691
sample estimates:
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## mean of x mean of y
## 2016.318 2167.035
# PGC1B plays a critical role in mitochondrial biogenesis.
# Transcript levels of this protein are significantly increased in FRDA
patients
# suggesting that patient cells may attempt to compensate for mitochond
rial dysfunction
# by upregulating mitochondrial biogenesis.
#PGC1beta Levels (encoded by gene PPARGC1B)
PGC1BLevels <- filter(GE, gene=="PPARGC1B")
ControlGroupPGC1B <- select(PGC1BLevels, starts_with("C"))
FAGroupPGC1B <- select(PGC1BLevels, starts_with("F"))
t.test(ControlGroupPGC1B, FAGroupPGC1B, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupPGC1B and FAGroupPGC1B
t = -3.2499, df = 22.256, p-value = 0.003635
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-25.074894 -5.547094
sample estimates:
mean of x mean of y
9.066452 24.377446

sd(ControlGroupPGC1B)/sqrt(length(ControlGroupPGC1B))
## [1] 1.74763
sd(FAGroupPGC1B)/sqrt(length(FAGroupPGC1B))
## [1] 4.375054
# Transcript levels of NFKB1, a subunit of the master transcriptional r
egulator NF-kB,
# are signfiicantly decerased in FRDA patients.
# NFKB1 Levels
NFKB1Levels <- filter(GE, gene=="NFKB1")
ControlGroupNFKB1 <- select(NFKB1Levels, starts_with("C"))
FAGroupNFKB1 <- select(NFKB1Levels, starts_with("F"))
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t.test(ControlGroupNFKB1, FAGroupNFKB1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupNFKB1 and FAGroupNFKB1
t = 3.0303, df = 32.893, p-value = 0.004733
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
102.5824 521.9362
sample estimates:
mean of x mean of y
1660.805 1348.546

# NLRP12 is involved in inflammasome activation.
# NLRP12 transcript levels are significantly increased in FRDA patients
,
# suggesting a potential role of inflammasome activation in FRDA.
# NLRP12 levels
NLRP12Levels <- filter(GE, gene=="NLRP12")
ControlGroupNLRP12 <- select(NLRP12Levels, starts_with("C"))
FAGroupNLRP12 <- select(NLRP12Levels, starts_with("F"))
t.test(ControlGroupNLRP12, FAGroupNLRP12, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupNLRP12 and FAGroupNLRP12
t = -2.9393, df = 26.556, p-value = 0.00673
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-17.01404 -3.01884
sample estimates:
mean of x mean of y
28.90673 38.92317

# The following protein transcripts did not show a significant differen
ce in FRDA patients.
# They were investigated because of their potential involvement in mito
chondrial dysfunctions in FRDA.
# BTRC Levels
BTRCLevels <- filter(GE, gene=="BTRC")
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ControlGroupBTRC <- select(BTRCLevels, starts_with("C"))
FAGroupBTRC <- select(BTRCLevels, starts_with("F"))
t.test(ControlGroupBTRC, FAGroupBTRC, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupBTRC and FAGroupBTRC
t = 0.26411, df = 27.759, p-value = 0.7936
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-36.06449 46.73610
sample estimates:
mean of x mean of y
450.5744 445.2386

# NFKB2 Levels
NFKB2Levels <- filter(GE, gene=="NFKB2")
ControlGroupNFKB2 <- select(NFKB2Levels, starts_with("C"))
FAGroupNFKB2 <- select(NFKB2Levels, starts_with("F"))
t.test(ControlGroupNFKB2, FAGroupNFKB2, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupNFKB2 and FAGroupNFKB2
t = -1.7903, df = 28.82, p-value = 0.08392
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-136.415563
9.084809
sample estimates:
mean of x mean of y
437.0860 500.7513

# IL1B Levels
IL1BLevels <- filter(GE, gene=="IL1B")
ControlGroupIL1B <- select(IL1BLevels, starts_with("C"))
FAGroupIL1B <- select(IL1BLevels, starts_with("F"))
t.test(ControlGroupIL1B, FAGroupIL1B, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##

Welch Two Sample t-test
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##
##
##
##
##
##
##
##
##

data: ControlGroupIL1B and FAGroupIL1B
t = -1.1096, df = 19.076, p-value = 0.2809
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-27.762889
8.521311
sample estimates:
mean of x mean of y
7.336399 16.957188

# NLRP1 levels
NLRP1Levels <- filter(GE, gene=="NLRP1")
ControlGroupNLRP1 <- select(NLRP1Levels, starts_with("C"))
FAGroupNLRP1 <- select(NLRP1Levels, starts_with("F"))
t.test(ControlGroupNLRP1, FAGroupNLRP1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupNLRP1 and FAGroupNLRP1
t = -1.3833, df = 31.664, p-value = 0.1762
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-252.73187
48.34702
sample estimates:
mean of x mean of y
769.1020 871.2945

# NLRP10 levels
NLRP10Levels <- filter(GE, gene=="NLRP10")
ControlGroupNLRP10 <- select(NLRP10Levels, starts_with("C"))
FAGroupNLRP10 <- select(NLRP10Levels, starts_with("F"))
t.test(ControlGroupNLRP10, FAGroupNLRP10, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupNLRP10 and FAGroupNLRP10
t = 0.28626, df = 31.043, p-value = 0.7766
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-28.51824 37.83148
sample estimates:
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## mean of x mean of y
## 60.24652 55.58989
#PGC1alpha Levels (encoded by gene PPARGC1A)
PGC1ALevels <- filter(GE, gene=="PPARGC1A")
ControlGroupPGC1A <- select(PGC1ALevels, starts_with("C"))
FAGroupPGC1A <- select(PGC1ALevels, starts_with("F"))
t.test(ControlGroupPGC1A, FAGroupPGC1A, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupPGC1A and FAGroupPGC1A
t = -0.76971, df = 32.264, p-value = 0.4471
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-67.46503 30.45243
sample estimates:
mean of x mean of y
56.07191 74.57821

# Tid1 Levels (encoded by the gene DNAJA3)
TID1Levels <- filter(GE, gene=="DNAJA3")
ControlGroupTID1 <- select(TID1Levels, starts_with("C"))
FAGroupTID1 <- select(TID1Levels, starts_with("F"))
t.test(ControlGroupTID1, FAGroupTID1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupTID1 and FAGroupTID1
t = 1.3818, df = 31.216, p-value = 0.1768
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-29.29669 152.49997
sample estimates:
mean of x mean of y
990.2590 928.6574

# GRP75 Levels (encoded by the gene HSPA9)
GRP75Levels <- filter(GE, gene=="HSPA9")
ControlGroupGRP75 <- select(GRP75Levels, starts_with("C"))
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FAGroupGRP75 <- select(GRP75Levels, starts_with("F"))
t.test(ControlGroupGRP75, FAGroupGRP75, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupGRP75 and FAGroupGRP75
t = 0.25178, df = 32.964, p-value = 0.8028
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-1019.199 1307.076
sample estimates:
mean of x mean of y
7061.775 6917.836

# Pink1 Levels
PINK1Levels <- filter(GE, gene=="PINK1")
ControlGroupPINK1 <- select(PINK1Levels, starts_with("C"))
FAGroupPINK1 <- select(PINK1Levels, starts_with("F"))
t.test(ControlGroupPINK1, FAGroupPINK1, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupPINK1 and FAGroupPINK1
t = -1.1071, df = 21.778, p-value = 0.2803
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-723.4902 220.0691
sample estimates:
mean of x mean of y
2660.809 2912.520

# PPARG Levels
PPARGLevels <- filter(GE, gene=="PPARG")
ControlGroupPPARG <- select(PPARGLevels, starts_with("C"))
FAGroupPPARG <- select(PPARGLevels, starts_with("F"))
t.test(ControlGroupPPARG, FAGroupPPARG, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##

Welch Two Sample t-test
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##
##
##
##
##
##
##
##
##

data: ControlGroupPPARG and FAGroupPPARG
t = -1.6196, df = 30.611, p-value = 0.1156
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-201.38498
23.16314
sample estimates:
mean of x mean of y
151.5573 240.6683

# TFAM Levels
TFAMLevels <- filter(GE, gene=="TFAM")
ControlGroupTFAM <- select(TFAMLevels, starts_with("C"))
FAGroupTFAM <- select(TFAMLevels, starts_with("F"))
t.test(ControlGroupTFAM, FAGroupTFAM, alternative = "two.sided",
mu = 0, paired = FALSE, var.equal = FALSE, conf.level = 0.95)
##
##
##
##
##
##
##
##
##
##
##

Welch Two Sample t-test
data: ControlGroupTFAM and FAGroupTFAM
t = -0.15532, df = 32.998, p-value = 0.8775
alternative hypothesis: true difference in means is not equal to 0
95 percent confidence interval:
-64.01809 54.93694
sample estimates:
mean of x mean of y
639.0713 643.6119
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